0001562884-17-000081.txt : 20171120 0001562884-17-000081.hdr.sgml : 20171120 20171120163142 ACCESSION NUMBER: 0001562884-17-000081 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171120 DATE AS OF CHANGE: 20171120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANNABIS SCIENCE, INC. CENTRAL INDEX KEY: 0001024626 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911869677 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28911 FILM NUMBER: 171214127 BUSINESS ADDRESS: STREET 1: 19800 MACARTHUR BLVD., SUITE #300 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 1-888-263-0832 MAIL ADDRESS: STREET 1: 19800 MACARTHUR BLVD., SUITE #300 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: GULF ONSHORE, INC. DATE OF NAME CHANGE: 20080520 FORMER COMPANY: FORMER CONFORMED NAME: Brighton Oil & Gas, Inc. DATE OF NAME CHANGE: 20070927 FORMER COMPANY: FORMER CONFORMED NAME: Brighton Oil & Gas DATE OF NAME CHANGE: 20070927 10-Q 1 cbis-20170930_10q.htm CANNABIS SCIENCE INC., 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission File Number: 001-28911

CANNABIS SCIENCE, INC.

(Exact name of registrant as specified in its charter)

Nevada	91-1869677
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

19800 MacArthur Blvd., Suite 300, Irvine, California	92612
(Address of principal executive offices)	(Zip Code)

(888)263-0832
(Registrant’ s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a not-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). [ ] Yes [X] No

Number of common shares issued and outstanding at September 30, 2017: 2,521,095,296

Number of common shares outstanding at October 16, 2017: 2,551,805,296

Number of Class A common shares outstanding at October 16, 2017: 0

CANNABIS SCIENCE, INC.

FORM 10-Q

For the Period Ended September 30, 2017

TABLE OF CONTENTS

	Page
PART I FINANCIAL INFORMATION	2
Item 1. Consolidated Financial Statements	2
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3. Quantitative and Qualitative Disclosures about Market Risk	10
Item 4. Controls and Procedures	10
PART II OTHER INFORMATION	10
Item 1. The Business	10
Item 1A. Risk Factors	11
Item 2 Legal Proceedings	13
Item 3. Unregistered Sales of Equity Securities and Use of Proceeds	13
Item 4. Defaults Upon Senior Securities	14
Item 5. Mine Safety Disclosures.	14
Item 6. Other Information	14
Item 7. Exhibits and Certifications	15

PART I FINANCIAL INFORMATION.

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CANNABIS SCIENCE, INC.

	Page No.

Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016	F-1

Consolidated Statements of Operations and Other Comprehensive Income (Loss) for the three and nine months ended September 30, 2017 and 2016	F-2

Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016	F-3

Consolidated Statements of Stockholders’ Deficit for the nine months ended September 30, 2017	F-4

Notes to Consolidated Financial Statements	F-5

CANNABIS SCIENCE, INC. CONSOLIDATED BALANCE SHEETS September 30, 2017 and December 31, 2016

	September 30, 2017			December 31, 2016
	(UNAUDITED)
	$			$
ASSETS
Current Assets
Cash		29,294			332,888
Other receivables		22,715			36,001
Prepaid expenses and deposits held with RMS (Note 11)		268,448			808,514
Inventory		151,675			102,993
Total current assets		472,132			1,280,396

Equipment and Greenhouse, net (Note 7)		321,370			—
Property Farming Rights (Note 8)		945,121			751,726
Equity method investee (Note 9)		202,477			272,644
Intangibles, net of accumulated amortization (Note 10)		139,750			172,000
TOTAL ASSETS		2,080,850			2,476,766

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable		773,950			856,269
Accrued expenses, primarily management fees (Note 4)		1,267,745			884,465
Advances from related parties (Note 4)		627,066			538,425
Management bonuses		300,000			300,000
Notes payable to stockholders (Note 5)		1,758,655			1,506,745
Notes payable to related party (Note 5)		510,018			177,698
Total current liabilities and total liabilities		5,237,434			4,263,602

Stockholders’ Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at
September 30, 2017 and December 31, 2016		1,000			1,000
Common stock, $.001 par value, 3,000,000,000 shares authorized,
2,521,005,296 issued and outstanding as of September 30,2017 and
2,350,355,296 at December 31, 2016		2,521,006			2,350,356
Common stock, Class A, $.001 par value, 100,000,000 shares
authorized, 0 issued and outstanding as of September 30, 2017 and December 31, 2016		—			—
Additional paid-in capital		148,164,025			136,963,520
Prepaid consulting		(3,674,296	)		(1,705,659	)
Common Stock receivable		(1,275,774	)		(655,000	)
Accumulated deficit		(148,335,348	)		(138,137,771	)
Cumulative exchange translation		(9,821	)		(11,495	)
Equity attributable to common shareholders		(2,609,208	)		(1,195,049	)
Non-Controlling interest		(547,376	)		(591,787	)
Total stockholders' deficit		(3,156,584	)		(1,786,836	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		2,080,850			2,476,766

The accompanying notes are an integral part of these consolidated financial statements.

F-1

CANNABIS SCIENCE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME(LOSS)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(UNAUDITED)


	For the three months						For the nine months
	ended September 30,						ended September 30,
	2017			2016			2017			2016
	$			$			$			$
REVENUE		2.317			2,733			6,302			8,520
Cost of Goods Sold		1,183			1,407			3,245			3,609
Gross Profit		1,134			1,326			3,057			4,911
Operating Expenses
Investor relations		170,339			48,950			310,450			267,300
Professional Fees		68,501			58,962			343,590			254,079
Net loss on settlement of liabilities		—			3,550,000			—			4,138,645
Loss on investment		—			971,500			—			971,500
Depreciation and Amortization		16,345			19,284			41,672			57,853
Research and Development		125,513			6,487			511,345			265,024
General and administrative		2,720,660			2,301,712			7,855,375			6,082,880
Total operating expenses		3,101,358			6,956,895			9,062,432			12,037,281
Net Operating Loss		(3,100,224	)		(6,955,569	)		(9,059,375	)		(12,032,370	)

Other income (expense)
Interest expense, net		(392,956	)		—			(1,022,541	)		(902	)
Unrealized loss on equity investee		(19,500	)		—			(71,250	)		—
Total other income (expense)		(412,456	)		—			(1,093,791	)		(902	)
Net Loss		(3,512,680	)		(6,955,569	)		(10,153,166	)		(12,033,272	)
Net (Income) loss attributable to non-controlling interest		1,344			—			(44,411	)		78,413
Net loss attributable to common shareholders		(3,511,336	)		(6,955,569	)		(10,197,577	)		(11,954,859	)
Other Comprehensive Income (Loss)
Foreign exchange translation adjustment		3,037			(201	)		1,674			392
Total other comprehensive income (Loss)		3,037			(201	)		1,674			392
Comprehensive loss attributable to Cannabis Science, Inc.		(3,508,299	)		(6,955,770	)		(10,195,903	)		(11,954,467	)

Net loss per common share:
Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)

Weighted average number of common shares outstanding		2,468,885,731			2,106,170,513			2,426,212,256			1,894,510,405

The accompanying notes are an integral part of these consolidated financial statements.

F-2

CANNABIS SCIENCE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 and 2016

(UNAUDITED)

	September 30, 2017			September 30, 2016
	$			$
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		(10,153,166	)		(12,033,272	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		169,527			57,853
Charitable donation		40,000			—
Interest on debt conversion		1,022,502			—
Stock issued for services		5,368,518			3,825,874
Stock options issued for services		1,909,000			1,138,500
Loss on investment		—			971,500
Loss on settlement of liability		—			4,138,645
Loss on Equity Investee.		71,250			—
Changes in operating assets and liabilities: Other receivables		13,286			4,173
Prepaid expenses and deposits held with RMS		438,816			11,250
Equity investee		(1,083	)		(321	)
Inventory		(48,682	)		(73,739	)
Property farming rights		(220,000	)		—
Accounts payable		292,681			411,616
Accrued expenses, primarily management fees		383,280			812,218
Loan receivable, related parties		88,641			—
NET CASH USED IN OPERATING ACTIVITIES		(625,430	)		(735,703	)
CASH FLOWS FROM INVESTING ACTIVITIES
Advances receivable, related parties		—			17,516
Prepaid Expenses		—			(244	)
Equipment and computers		(766	)		—
Greenhouse		(330,026	)		—
Property farming rights		—			(48,611	)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES		(330,792	)		(31,339	)
CASH FLOWS FROM FINANCING ACTIVITIES
Loan receivable, related parties					82,369
Proceeds from notes payable to stockholders					295,855
Repayment of notes payable to stockholders		(438,272	)		(295,000	)
Proceeds from common stock options exercised		1,089,226			632,500
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		650,954			715,724

Effect on exchange rate changes on cash		1,674			392
NET DECREASE IN CASH		(303,594	)		(50,926	)
CASH, BEGINNING OF PERIOD		332,888			61,971
CASH, END OF PERIOD		29,294			11,045

SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for services		5,368,518			1,816,732
Common stock issued for settlement of debt		—			4,434,500
Common stock issued for options exercised		1,909,000			3,888,500
Common stock issued for assets					271,350
Debt converted into common stock		—			295,000
Common stock subscription receivables		1,275,774			2,499.000
Related Party Receivable - RCDU		—			20,000
Accounts payable and expenses paid through advances from related parties		88,641			29,852

The accompanying notes are an integral part of these consolidated financial statements.

F-3

CANNABIS SCIENCE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED September 30, 2017

	Common Shares		Par		Preferred Shares		Par		Additional Paid-In Capital		Prepaid Consulting			Common Stock Receivable			Accumulated Deficit			Cumulative Exchange Translation			Equity Attributable to Common Shareholders			Non-Controlling Interest			Totals
			$				$		$		$			$			$			$			$			$			$
Balance at December 31, 2016		2,350,355,296		2,350,356		1,000,000		1,000		136,963,520		(1,705,659	)		(655,000	)		(138,137,771	)		(11,495	)		(1,195,049	)		(591,787	)		(1,786,836	)
Common stock issued for services		110,650,000		110,650						7,226,505		(3,816,075	)											3,521,080						3,521,080
Issuance and exercise of stock options		60,000,000		60,000						3,599,000					(620,774	)								3,038,226						3,038,226
Intrinsic interest on convertible promissory notes										375,000														375,000						375,000
Amortization of shares issued for services												1,847,438												1,847,438						1,847,438
Net loss for the period																		(10,197,577	)					(10,197,577	)		44,411			(10,153,166	)
Foreign exchange translation																					1,674			1,674						1,674
Balance at September 30, 2017		2,521,005,296		2,521,006		1,000,000		1,000		148,164,025		(3,674,296	)		(1,275,774	)		(148,335,348	)		(9,821	)		(2,609,208	)		(547,376	)		(3,156,584	)

The accompanying notes are an integral part of these consolidated financial statements.

F-4

CANNABIS SCIENCE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2017

(UNAUDITED)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Organization and General Description of Business

Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.

On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC Pink: CBIS.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 ^th and May 6 ^th, 2013, respectively, to pursue business opportunities in Europe and worldwide. There are currently minimal operations in the subsidiaries. Agreements and business disclosures are in process.

On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neuro behavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neuro behavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.

B. Basis of Presentation

These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year end is December 31.

Interim Financial Reporting

While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2016 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine-month periods ended September 30, 2017 and 2016. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2016 included in our Form 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.

F-5

The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the nine months ended September 30, 2017:

In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) in which the Company own 90% to operate joint-venture operations with Dupetit Natural Products Ltd. The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012. No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany.

On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV, MJR BV and Cannabis Agency BV, all are Netherlands registered companies.

On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT.

On May 6, 2015, the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. in the state of Tennessee and started the operation of distributing of existing and new line of products.

On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with JinvatorBioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. Jinvator developed a prototype called nanoGold-Test which is based on nano-particle technology for the detection of HIV in the early stage of infection. Patent has been submitted and pending for approval.The acquisition is pending on verification of key information.

On March 27, 2017, the Company entered an agreement to acquire the Assets of AFA Research and Development, a California sole proprietorship of Aja Fonseca Arnold in the research and development of products based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.

For other accounting policies please refer to the Company’s 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017.

F-6

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

2. GOING CONCERN

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of $148,335,348 and had a stockholders’ deficit of $3,156,584 as of September 30, 2017.

In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At September 30, 2017, the Company had insufficient operating revenues and cash flow to meet its financial obligations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We anticipate that we will have to raise additional capital to fund operations over the next 12 months. To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings.

Any future financing may involve substantial dilution to existing investors. We had been relying on our common stock to pay third parties for services which has resulted in substantial dilution to existing investors.

3. FAIR VALUE MEASUREMENTS AND DISCLOSURES

ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

4. RELATED PARTY TRANSACTIONS

At September 30, 2017, a total of $229,180 (December 31, 2016: $14,200) in Accrued Management Fees Payable was due to the Company’s CEO/Director, Raymond C. Dabney.

At September 30, 2017, a total Prepaid management fees of $30,000 (December 31, 2016: Prepaid $52,500) advanced to the Company’s Director, Mario Lap.

At September 30, 2017, a total of $105,000 (December 31, 2016: Prepaid $30,000) in Accrued Management Fees Payable was due to the Company’s COO/Director, Robert Kane.

At September 30, 2017, a total of $52,000 (December 31, 2016: $52,500) in loans payable was due to the Company’s CFO, Robert Kane, through his company, R Kane Holding Inc., secured by a non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.

At September 30, 2017, the Company owes $11,871 (December 31, 2016: $11,871) to Crown Baus Capital Corp., which advanced a total of $11,871 for payment of the Company’s expenses in July, August and September of 2015 with no interest and no security. Crown Baus Capital Corp. is a company controlled by Raymond C. Dabney.

F-7

As of September 30, 2017, the Company owes $101,882 (December 31, 2016: $101,882) in loan payable to a stockholder, Interstate 101 that is non-interest bearing and due on demand with no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.

At September 30, 2017, the Company owes $3,165 (December 31, 2016: $3,165) in loan payable to Castor Management Services, a shareholder of the Company, with no interest and no security and is due on demand. The loan originated on August 14, 2015 for expenses of the Company.

At September 30, 2017, a total of $191,344 (December 31, 2016: $191,344) in loans payable was due to Bogat Family Trust, of which Raymond Dabney the Company’s Director and President/CEO as trustee.

At September 30, 2017, $106,186 (December 31, 2016: $93,885) was due to MJR BV, owned by Mario Lap director and director and officer of EU subsidiaries.

At September 30, 2017, $447 (December 31, 2016: $447) was due to Robert Melamede, former CEO.

At September 30, 2017, a total of $95,909 (December 31, 2016: $23,378) in loans payable was due to Drue Young, a shareholder of the Company, with no interest and no security and is due on demand. The loan originated from January 11, 2016 to September 30, 2017 for expenses of the Company.

At September 30, 2017, a total of $20,502 (December 31, 2016: $20,502) in loans payable was due to Intrinsic Venture Corp., a shareholder of the Company, with no interest and no security and is due on demand. The loan originated from April 22, 2011 to December 31, 2014.

At September 30, 2017, the Company held 7,500,000 common shares in the OmniCanna Health Solutions, Inc. (prior to April 24, 2014, the name was Endocan Corporation) (OTCBB: ENDO) (“OmniCanna”) representing approximately 2.89% of the issued and outstanding shares of OmniCanna, of which 5,000,000 common shares were acquired at a fair market value of $150,000 or $0.03 per share on December 12, 2012 and 2,500,000 common shares were acquired at a fair market value of $262,250 or $0.1049 per share on February 8, 2013. The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the Dupetit Natural Products GmbH joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement. The value of the shares at September 30, 2017 was determined to be $0.0155 per share or $116,250 with the Company recording unrealized loss under the Equity Investee rules for the nine months ended September 30, 2017 and the value of the shares at December 31, 2016 was determined to be $0.025 per share or $187,500.

Convertible Notes Payable to Royalty Management Services Corp., a company owned by a family member of Mr. Raymond C. Dabney, CEO/Director of the Company, entered into a management agreement with the Company on September 15, 2015 for accounting services, websites development and maintenance, office management, management and payments for travel, promotion and entertainments, shareholders communications and payment services totaled $797,518 and $860,790 at September 30, 2017 and December 31, 2016 respectively. See Note 5.

On July 2, 2017, the Company donated $40,000 to Constituency For Africa, a charitable organization found in United States for the people in Africa, of which Mr. Raymond C. Dabney is a Board member.

On November 5, 2014, the Company transitioned to equity method investee accounting for the OmniCanna shares pursuant to ASC 323 recording $247,500 as the fair value of the shares to its equity method investee account. On December 31, 2016, the Company recorded an impairment on the equity method investee account of $144,000 in relation to the shares. Robert Kane, COO and director of the Company is also the COO and a director of OmniCanna. Benjamin Tam, CFO, and a director is also a director and CFO of Omnicanna. Raymond Dabney, CEO has 10.78% equity interest in Omniccanna Health Solutions, Inc. as of September 30, 2017.

F-8

For the nine months ended September 30, 2017, the following related party stock-based compensation was recorded:

Related Party	Position	Amount
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH	$	415,000
Dr. Allen Herman	Chief Medical Officer		595,000
		$	1,010,000

¹Including compensation to entities beneficially owned/control by the related parties

See Note 6 -Equity Transactions for details of stock issuances to director and officers for services rendered.

Mario Lap, a director of the Company and director and officer of its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MJR BV, MLS Lap BV and Cannabis Agency BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. The Company anticipates having the Spanish subsidiary setup soon at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company.

Alfredo Dupetit-Bernardi, International Product Development and President & CEO of Cannabis Science Europe GmbH, is conducting product development through the purchase of cannabis products from his personal company, Dupetit Natural Products GmbH.

On August 10, 2016, a total of $975,407 in Management Fees Payable accumulated from February 2012 to September 30, 2016 was converted into a two-year Convertible Promissory Note to Raymond C. Dabney, CEO/Director of the Company. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company paid $55,000 in expenses for Mr. Dabney in 2016. The balance of the Convertible Promissory Note as of September 30, 2017 was $670,407 (December 31, 2016: $670,407).

Notes payable to Embella Holdings Ltd. totaled $1,108,896 and $1,108,896 at September 30, 2017 and December 31, 2016, respectively. As of September 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. See Note 5.

Notes payable to Intrinsic Capital Corp. totaled $231,260 and $231,260 at September 30, 2017 and December 31, 2016, respectively. See Note 5.

Between January 1, 2015 to March 7, 2015, R. Kane Holding Inc., a company owned by Mr. Robert Kane, director and CFO, had advanced $52,500 into Michigan Green Technologies, LLC, which is 50.1% controlled by the Company as Loan Payable to R. Kane Holding Inc.

On July 25, 2014, Bogat Family Trust, with Raymond Dabney as trustee, representing a majority of Series A preferred stockholders, signed a resolution to approve an amendment to the certificate of designation preferences and rights for Series A preferred shares. Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters. No common stockholders voted on this amendment.

F-9

5. NOTES PAYABLE

As of September 30, 2017, a total of $1,758,655 (December 31, 2016: $1,506,745) of notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 2016. $1,340,156 of the Promissory notes were in default on September 30, 2017. As of September 30, 2017, a total of $1,467,925 convertible promissory notes (December 31, 2016: $1,531,197) are convertible to common stock of the Company. All promissory notes are unsecured.

Notes payable to Embella Holdings Ltd that are non-interest bearing totaled $1,108,896 and $1,108,896 at September 30, 2017 and December 31, 2016, respectively. As of September 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. The note payable is classified with notes payable to stockholders.

Notes payable to Intrinsic Capital Corp. that are non-interest bearing totaled $231,260 and $231,260 at September 30, 2017 and December 31, 2016, respectively. As of September 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. The note payable is classified with notes payable to stockholders.

On August 10, 2016, a total of $975,407 in Management Fees Payable accumulated from February 2012 to June 30, 2016 was converted into a two-year Convertible Promissory Note to Raymond C. Dabney, CEO/Director of the Company. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and will amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company paid $55,000 in expenses for Mr. Dabney in 2016. The balance of the Convertible Promissory Note as of September 30, 2017 was $670,407 (December 31, 2016: $670,407). In the nine months ended September 30, 2017, the Company recorded $251,910 as interest for the amortization, conversion and payment. The note payable is classified with notes payable to stockholders.

On October 1, 2016, a total of $710,790 in Accounts Payable for management fees accumulated from January 2016 to October 1, 2016 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp., a related party. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The Company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The Company paid $438,272 during the period from July 2, 2017 to September 30, 2017 to Royalty Management Services Corp., a related party. The balance of the Convertible Promissory Note as of September 30, 2017 was $272,518 (December 31, 2016: $710,790). In the nine months ended September 30, 2017 the Company recorded $533,092 as interest for the amortization, conversion and payment.

On December 31, 2016, $150,000 in Accounts Payable for management fees accumulated from November 1, 2016 to December 31, 2016 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp., a related party. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The balance of the Convertible Promissory Note as of September 30, 2017 was $150,000 (December 31, 2016: $150,000). In the nine months ended September 30, 2017 the Company recorded $112,500 as interest for the amortization, conversion and payment.

On May 31, 2017, $375,000 in Accounts Payable for management fees accumulated from January 1, 2017 to May 31, 2017 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp., a related party. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The balance of the Convertible Promissory Note as of September 30, 2017 was $375,000 (December 31, 2016: $0). In the nine months ended September 30, 2017 the Company recorded $125,000 as interest for the amortization, conversion and payment.

F-10

6. EQUITY TRANSACTIONS

The Company is authorized to issue 3,000,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 2,521,005,296 and 2,350,355,296 issued and outstanding as of September 30, 2017 and December 31, 2016, respectively. The current authorized common stock of 3,000,000,000 shares will not be sufficient if and when the debt holders of convertible promissory notes elect to convert the debts into common shares. The Company intends to file for an increase in the number shares in authorized common stock once the required updated financial reporting have been filed with the Securities Exchange Commission.

The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share. These shares have 10 votes per share. There were 0 issued and outstanding as of September 30, 2017 and December 31, 2016.

The Company is also authorized to issue 1,000,000 shares of preferred stock. These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State. There were 1,000,000 issued and outstanding as of September 30, 2017 and December 31, 2016.

As set out below, we have issued securities in exchange for services, properties and for debt, using exemptions available under the Securities Act of 1933.

During the nine months ended September 30, 2017, the Company issued 121,500,000 shares of common stock and cancelled 10,850,000 pending to be issued shares of common stock for services under various executive and consulting agreements as follows:

On February 16, 2017, the Company issued 5,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $350,000 for legal and general consulting services under a consulting agreement dated January 13, 2017.

On February 16, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock to a consultant with a fair market value of $700,000 for legal and general consulting services pursuant to a consulting agreement dated January 13, 2017.

On March 2, 2017, the Company issued 3,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $271,500 for consulting services pursuant to a two-year consulting agreement.

On March 7, 2017, the Company issued 15,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,270,500 for consulting services under a consulting agreement dated March 7, 2017.

On March 13, 2017, the Company issued 10,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $883,000 for consulting services pursuant to a consulting agreement dated July 6 2016.

On March 13, 2017, the Company issued 15,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,324,500 for consulting services pursuant to a consulting agreement dated April 29, 2015.

On May 5, 2017, the Company issued 7,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $469,000 for consulting services pursuant to a one year consulting agreement.

On May 17, 2017, the Company issued 1,500,000 shares of R144 restricted common stock to a consultant with a fair market value of $93,600 for consulting services pursuant to a three-month Marketing agreement.

On August 10, 2017, the Company issued 25,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,062,500 for consulting services pursuant to a two-year consulting agreement.

F-11

On August 31, 2017, the Company issued 30,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,392,000 for bonus to a consultant pursuant to a two-year consulting agreement dated August 10, 2017.

On September 30, 2017, the Company cancelled 3,500,000 shares of R144 restricted common stock, which were pending to be issued since 2015 to two consultants shares with a total fair market value of $107,750 based on the date of the Consultant Agreements, for non-performance of services.

On September 30, 2017, the company cancelled 7,350,000 shares S-8 registered free trading common stock, which were pending to be issued from 2014 to 2016 with a total fair market value of $371,695 based on the date of the Consultant Agreement, for non-performance of services.

Stock Options:

The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement:

(i)

the option to purchase 100,000 common shares at ten cents ($0.10) per share;

(ii)

the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and

(iii)

the option to purchase 100,000 common shares at twenty cents ($0.20) per share;

(iv)

the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.

On January 13, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.05 and a fair market value of $700,000 to a consultant pursuant to a consulting agreement.

On January 24, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.04 and a fair market value of $815,000 to Alfredo Dupetit-Bernardi, President/CEO of Cannabis Science Europe GmbH.

On March 27, 2017, the Company issued 15,000,000 shares S-8 registered free-trading common stock under the 2016 Equity Award Plan B with exercise price at $0.075 and a fair market value of $1,140,000 to a consultant pursuant to a five-year consulting agreement. On September 29 2017, by mutual agreement, the Company and the Consultant agreed to cancel the 15,000,000 shares issued and these shares are to be returned to treasury for cancellation.

On April 18, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 and a fair market value of $829,000 to Chief Medical Officer, Dr. Allen Herman.

On August 2, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.015 and a fair market value of $465,000 to a consultant pursuant to a consulting agreement.

On August 10, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement.

On August 10, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.03 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement.

F-12

A summary of the status of the Company’s option grants as of September 30, 2017 and the changes during the period then ended is presented below:

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2016		11,700,000	$	0.069
Granted		75,000,000	$	0.064
Exercised		75,000,000	$	0.064
Expired		10,000,000	$	0.010
Outstanding September 30, 2017		1,700,000	$	0.041

Options exercisable at September 30, 2017		1,700,000	$	0.041
Shares issued under option agreement to be returned and cancelled		15,000,000	$	0.075

1,700,000 shares of these options at an average exercise price of $0.41 a share, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane. The weighted average fair value at date of grant for options during year ended September 30, 2017 was estimated using the Black-Scholes option valuation model with the following:

Average expected life in years for outstanding options	2	Years
Average risk-free interest rate	2.50	%
Average volatility	137.2697	%
Dividend yield	0	%

7. EQUIPMENT AND GREENHOUSE

			Accumulated		September 30, 2017		December 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Computer	$	6,482	$	5,971	$	511	$	0
Software		5,000		5,000		0		0
		11,482		10,971		511		0
Greenhouse	$	330,026	$	9,167	$	320,859	$	0
Total	$	341,508	$	20,138	$	321,370	$	0

8. PROPERTY FARMING RIGHTS

On March 24, 2016, the Company entered a 15 years Joint Venture Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two initial payments of $50,000 for farming rights and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.

On October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is 40% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.

F-13

On November 12, 2016, the Company entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On December 18, 2016, the Company enter six (9) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On December 21, 2016, the Company enter two (2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On May 18, 2017, the Company entered an Exclusive Master Facilitator Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit Organics, LLC (FSO), American Education Consulting Group, Raymond C. Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to lease and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and retain 5% of net profit as master facilitator.The Company wrote off the operating capital in the amount of $212,000 for Winnemucca Lands inclusive of HRM Farm due to the illegal seizure of cultivated industrial hemp by San Joaquin County and Department of Enforcement Agency (DEA) on October 9, 2017. The Company has filed a suit against the San Joaquin County and DEA on October 27, 2017.

F-14

					September 30, 2017		December 31, 2016
	Cost		Accumulated Depletion		Net Book Value		Net Book Value
Property Farming Rights
Fort McDermit Allottees Land	$	50,000	$	4,723	$	45,277	$	47,778
Washoe Tribal Allotment Lands		640,000		20,252		619,748		638,948
Winnemucca Tribal MBS Lands		200,000		4,904		195,096		0
		890,000	$	29,879		860,121		686,726
Operating capital for Washoe Lands	$	85,000		—	$	85,000	$	—
Total	$	975,000	$	29,879	$	945,121	$	686,726

All equipment is stated at cost. Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized. Depreciation is computed using the straight-line method over the estimated lives of the related assets, 2 years for computer, 2 years for software, 5 years for equipment and laboratory equipment and 3 years for automobile.

All property farm rights are amortized over the term of each respective agreements.

9. EQUITY METHOD INVESTEE

On November 5, 2014, the Company accounted for its investment and loans in OmniCanna Health Solutions, Inc. (formerly Endocan Corporation) using the equity method pursuant to ASC 323 – Investments – Equity Method and Joint Ventures. In accordance with ASC 323, when the Company does not have a controlling financial interest in an entity but exerts significant influence over the entity’s operating and financial policies, the Company accounts for its investment in accordance with the equity method of accounting. This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.

The accounting using the equity method is in conjunction with appointment of Raymond Dabney as CEO and director of the Company on November 5, 2014, in addition to Mr. Dabney being a controlling shareholder of the Company since September 2009 and a 10.78% equity interest in OmniCanna since June 2013. Benjamin Tam, CFO and director and Robert Kane, COO and director of the Company are also the CFO and director and COO and director of Omnicanna. Therefore, the Company was deemed to have significant influence and control of OmniCanna Health Solutions, Inc.

On November 5, 2014, the Company recorded $247,500 in marketable securities and $85,277 (based on currency converted as of September 30, 2017) in loans to OmniCanna and to its equity method investee account in accordance with ASC 323. An unrealized loss on the equity method account of $71,250 was recognized for the nine months ended September 30, 2017 in addition to a unrealized gain on the equity method investee account of $144,000 was recognized for the year ended December 31, 2016 in the value of Omnicanna marketable securities.

10. GOODWILL and INTANGIBLE ASSETS

	September 30, 2017			December 31, 2016
Intellectual assets, primarily intellectual property	$	660,299		$	660,299
Goodwill		170,688			170,688
Less: accumulated amortization		(520,549	)		(488,299	)
Less: Impairment of Goodwill		(170,688	)		(170,688	)
Total intangible assets, net	$	139,750		$	172,000

Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for both intellectual assets and Goodwill).

F-15

11. PREPAID EXPENSES AND DEPOSITS HELD WITH RMS

On October 1, 2016, the Company entered a Paying Agent Agreement with Royalty Management Services Corp. (RMS) for holding funds and making payment for expenses and commitments of the Company. The Company has entered a Management Agreement with RMS since September 15, 2016 for management, investors’ and shareholders’ communications, website development, database management, accounting and management of all activities such as travel and conference. All the expenses related to the services for the Company are included as part of the management fees.

	September 30, 2017		December 31, 2016
Prepaid consulting expenses	$	130,500	$	141,750
Prepaid Legal fees		—		90,000
Prepaid rent		244		244
Prepaid management fees		30,000		—
Deposits held with RMS		42,490		576,520
Deposit for acquisition of Jinvator		65,214		—
Total Prepaid expenses and Deposits held with RMS	$	268,448	$	808,514

12. COMMITMENTS

The Company has lease commitments for its European operations under private companies, MLS Lap B.V. and MJR B.V. owned and controlled by Mario Lap, director of the Company and director and officer of EU subsidiaries. Negotiations are ongoing in regards to preparing finalized agreements between the Company and Mr. Lap’s companies.

13. SUBSEQUENT EVENTS

On October 17, 2017, the Company issued 20,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.025 and a fair market value of $610,000 to a consultant.

On October 27, 2017, the Company filed a suit against San Joaquin County and DEA for illegal seizure of cultivated industrial hemp crops from HRM Farm in Winnemucca Tribal Land for return of the seized properties.

F-16

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This section of this report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking states are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

Overview of the Company’s Business

Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.

Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.

CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.

CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.

In November 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neuro behavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neuro behavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neuro behavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with a strategic partner and related company, OmniCanna Health Solutions, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade product development.

Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

Some key phytocannabinoids are:

•

tetrahydrocannabinol (THC)

•

cannabidiol (CBD)

•

cannabigerol (CBG)

•

cannabichromene (CBC)

•

cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC.

Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

The Company’s future endeavors include infectious illnesses, neuro behavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.

We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions.

On March 30, 2009, the Company entered into an agreement with Cannex Therapeutics, LLC, (“Cannex”) a California limited liability company, and its principal, medical cannabis pioneer and entrepreneur Steven W. Kubby, to acquire all of their interest in certain assets used to conduct a cannabis research and development business. The asset purchase agreement includes all of Cannex’s and Kubby’s intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the website www.phytiva.com. The Company and its largest shareholder, K & D Equities, Inc., exchanged a total of 10,600,000 shares of common stock for the assets of Cannex; the Company issued 2,100,000 shares to Cannex, and K & D transferred 8,500,000 shares to Cannex and others. A Form 8-K reflecting this transaction was timely filed.

As part of the Agreement, on April 1, 2009, the Company appointed Mr. Kubby as President and CEO, Richard Cowan as Director and CFO, and Robert Melamede Ph. D., as Director and Chief Science Officer. Each of them was also appointed as a director. All of the Company’s current directors then resigned. On April 7, 2010, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. Its shares now trade under the symbol CBIS.OB. A Form 8-K was timely filed, with a copy of the Asset Acquisition Agreement and Board Resolution ratifying the Agreement provided as exhibits thereto.

On April 7, 2009, the Company changed its name to Cannabis Science, Inc., reflecting its new business mission: Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company obtained a new CUSIP number as well. Cannabis Science Inc. has also launched its new website www.cannabisscience.com reflecting its new name.

On May 7, 2009, the Company common shares commenced trading under the new stock symbol OTC: CBIS.

The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10^th and May 6^th , 2013, respectively, to pursue business opportunities in Europe and worldwide.

There are minimal operating activities in the subsidiaries as of September 30, 2017,. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MLS Lap B.V., MJR B.V. and Cannabis Agency B.V. until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time.

On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT that would increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued a total of twenty million (20,000,000) shares to the principals and shareholders of MGT over 12 months (see Form 8-K with the SEC on file no. 000-28911 August 8, 2014).

On January 5, 2015 the Company announced the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities. The products were for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution.

On May 7, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. The Company is working closely with management of Equi-Pharm to expand the product lines.

On May 19, 2015 Cannabis Science announced the expansion of licensing deal with Purple Haze Properties. Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products using scientific genetics and creating an education platform to share information from doctors and patients around the world about the advances of cannabis research.

On May 27, 2015 the Company announced a Historic Collaborative Drug Development deal with IGXBio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates. IGXBio is a privately held clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection, based in Fairway, KS, USA.

On July 16, 2015 Cannabis Science announced guidance in regards to its State-by-State initiatives, including its new product releases. On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.

On November 2, 2015, the Company announced a significant collaborative drug development deal with IGXBio Inc., and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies developed joint protocols that explore potential synergistic effects of their respective drug candidates, as well as potential new drug candidate opportunities. IGXBio has a drug called GenePro®, which is already registered with the FDA and has an IND number. This expedites the process to seek FDA approval in the future. GenePro® is designed to promote an anti-HIV immune response that facilitates virus control in HIV-infected subjects. There are more than 150 peer-reviewed publications that describe the effectiveness of GenePro®. The inflammatory response that is associated with HIV infection is present at even low levels of viral replication, and is a major causal factor for the morbidities and associated mortality of HIV infection. Low-grade inflammation frequently occurs despite clinically successful anti-retroviral therapy and is associated with increased incidence of heart disease, bone disease, and cancers.

On November 11, 2015, Cannabis Science announced the release of seven original cannabinoid-based animal care products through its wholly owned subsidiary, Equi-Pharm, LLC.

On November 25, 2015, the Company announced positive results from its initial test run of its Pure Decarboxylated CO2 Oil (PDCO) released through the Cannabis Science Research Foundation (CSRF or the Foundation) to 15 dispensaries and several less fortunate self-medicating patients. This trial, collaborative rollout by CSRF, as contracted by Cannabis Science to the California not-for-profit, was designed to meet two primary goals. The first, to conduct tests on the efficacy of the product for patients; the second, to gather proprietary data based on testimonials from real self-medicating consumers from their firsthand experiences. The feedback received will be used to influence the Company's continuing efforts to bring the best cannabinoid-based formulations to market On November 30, 2015 Cannabis Science announced the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are CBD, Indica, and Sativa; each of the three types of caps will be available in 25mg, 50mg, and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.

On December 10, 2015, the Company announced that Cannabis Science entered Select, New High-Dosage product line of CBD, Sativa, and Indica Capsules into the Industry-Famous Emerald Cup Event in Santa Rosa, CA on December 12^th and 13^th.

On December 15, 2015 after successful formulation work, Cannabis Science follows through with a full clinical drug development agreement with ImmunoClin to deliver GMP quality pre-clinical data to enter CS-NEURO-1 into a Phase I human study in Europe. After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

On March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made an initial payment of $50,000 for farming rights and initial development of the first two one (1) acre parcel of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjust Gross Income after deduction of related operating expenses and cost to build the green houses.

On December 18, 2016, the Company enter six (6) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years. On December 23, 2016, the Company paid $100,000 to the property owner members under the agreements and record the unpaid balance of $420,000 in accounts payable.

On January 3, 2017, the Company entered a Research Collaboration Agreement with Dana-Farber Cancer Institute, Inc. of Boston Massachusetts for a research project to develop and investigate the use of Cannabinolds to cure various caner, and investigate synergies with radiotherapy and immunotherapy. In consideration for this Agreement and performance of the Research, the Company has paid $201,656 to Dana-Farber Cancer Institute, Inc.

On May 10, 2017, the Company paid €60,000, which has a US dollar equivalent of $65,214, to the principal shareholder of JinvatorBioMed GmbH (Jinvator) as deposit for the purchase of the 74.9 equity interest in Jinvator. On September 5, 2017, Cannabis Science Europe GmbH sent a notice to the principal shareholder of Jinvator to cancel the share acquisition for Jinvator failed to disclose liabilities in the financial statements provided before the completion date and demanded the return of the deposit of €60,000.

On April 27, 2017, the Company entered a five-year Research Collaboration Agreement with DFCI for a research project to develop and investigate the use of Cannabinolds to cure various forms of cancer and investigate synergies with radiotherapy and immunotherapy. In consideration for this agreement and performance of the research, the Company is obligated to pay DFCI a total of $1,834,062 over the life of the agreement with $159,287 due at signing and $418,683 to be paid at each anniversary of the agreement for the next four years.

The Company is working on several business acquisition and development projects to increase business and revenue generation in 2017 and beyond, including but not limited to: product licensing and royalty agreements, private label hemp product line, consulting, and other strategic acquisitions to support product development, production, and distribution of newly acquire or manufactured cannabis and hemp based products. There can be no assurance that these will be successful in generating revenues in 2017.

Liquidity

The Company has a working capital deficit of $4,765,302 as of September 30, 2017, compared to a working capital deficit of $2,983,206 as of December 31, 2016,There are insufficient liquid assets to meet current liabilities or sustain operations through 2017 and beyond and the Company must raise additional capital to cover the working capital deficit. Management is working on plans to raise additional capital through private placements and lending facilities. The Company currently is relying on existing cash and loans from stockholders to meet its obligations and sustain operations.

The Company has promissory note payment commitments of $1,340,156 due to stockholders and currently is in default. The Company is negotiating with the debtors to extend the notes payable. In addition, the Company has convertible promissory notes payment commitment of $670,407 to Raymond C. Dabney, CEO/Director of the Company and $797,518 to Royalty Management Services Corp.

Contractual Obligations

The Company has various commitments under consulting contracts, debt settlement, farming rights agreements, laboratory services agreement, joint development, and joint venture agreement.

Capital Resources

The Company has additional capital resource requirements for personnel, supplies, research and development, laboratory, cultivation equipment, green houses and scientific equipment of approximately $6,000,000 over the next 12 months. These capital disbursements are dependent on management’s successful raising of capital through private placements and/or lending facilities.

The Company is not currently in good short-term financial standing. We anticipate that we may only generate limited revenues in the near future and we will not have enough positive internal operating cash flow until we can generate substantial revenues, which may take the next two years to fully realize. There is no assurance we will achieve profitable operations. We have historically financed our operations primarily by cash flows generated from the sale of our equity securities and through cash infusions from officers and outside investors in exchange for debt and/or common stock.

Results of Operations

For the nine months ended September 30, 2017 (“2017”) as compared to the prior year nine months ended September 30, 2016 (“2016”):

The Company had $6,302 in revenues for the 2017 compared to $8,520 for 2016. This decrease in revenue was due to reduction of sales of Equi-Pharm and license revenue from product sales.

Our research and development expenses increased by $246,321 to $511,345 for the nine months ended September 30, 2017 compared to $265,024 for the nine months ended September 30, 2016.

Our unrealized loss on equity investee increased by $71,250 to $71,250 for the nine months ended September 30, 2017 compared to $0 for the nine months ended September 30, 2016.

Net loss on settlement of debt decreased by $4,138,645 to $0 for the nine months ended September 30, 2017 compared to $4,138,645 for the nine months ended September 30, 2016.

General and administrative expenses increased by $1,772,495 to $7,855,375 for the nine months ended September 30, 2017 compared to $6,082,880 for the nine months ended September 30, 2016. This increase was due to higher share prices in the stock compensation expense pursuant to management consulting and bonus agreements.

The Company is working on several business development projects to generate revenues, including: investing in the cultivation of leased properties with Members of the Washoe Tribal Allotment, Winnemucca Tribal Allotment, HRM Farm and Free Spirit Organics, LLC in Nevada and California that will generate increased license, royalty revenue, Cannabis/Hemp products sales, and other strategic acquisitions to support product development, production, and distribution of newly acquired or manufactured cannabis and hemp based products. The Company’s drug development through its laboratory services to facilitate new inhalation study for asthma/COPD and other respiratory conditions. In addition, the Company signed an agreement with Equi-Pharm for the commercialization of pet products for distribution in California. Notwithstanding, there can be no assurance that these will be successful in generating revenues in 2017.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report, have concluded that, based on the evaluation of these controls and procedures, that our disclosure controls and procedures were not effective.

There were no changes in our internal controls or in other factors during the last fiscal quarter covered by this report that have materially affected, or are likely to materially affect the Company’s internal controls over financial reporting.

PART II OTHER INFORMATION

ITEM 1. BUSINESS

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This Interim Report on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statements. Discussions containing forward-looking statements may be found in the material set forth under “Business,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Interim Report on Form 10-Q. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.

Readers should carefully review and consider the various disclosures made by us in this Report, set forth in detail in Part I, under the heading “Risk Factors,” as well as those additional risks described in other documents we file from time to time with the Securities and Exchange Commission, which attempt to advise interested parties of the risks, uncertainties, and other factors that affect our business. We undertake no obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

As used in this Form 10-Q, the terms "we", "us", "our", “the Company”, and "Cannabis Science" mean Cannabis Science, Inc., unless otherwise indicated.

All dollar amounts refer to U.S. dollars unless otherwise indicated.

Overview

Cannabis Science, Inc. (“We” or the “Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.

On May 7, 2009 the Company’s common shares commenced trading under the new stock symbol OTCQB: CBIS.

Currently, the Company’s common shares are trading under the OTC Pink Sheets market with symbol CBIS.

ITEM 1A. RISK FACTORS

The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding any statement in this Form 10-Q or elsewhere. The following information should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-Q.

Because of the following factors, as well as other factors affecting the Company’s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

The Company is subject to laws and regulations worldwide, changes to which could hinder the Company’s medical cannabis research and increase the Company’s costs and individually or in the aggregate adversely affect the Company’s business.

The Company is subject to laws and regulations affecting its domestic and international operations in medical research and production of medical cannabis. These U.S. and foreign laws and regulations affect the Company’s activities including, but not limited to, areas of sales to only certain legalized regions, labor, advertising, digital content, product label, consumer protection, billing, e-commerce, promotions, quality of services, media, television, intellectual property ownership and infringement, tax, import and export requirements, foreign exchange controls and cash repatriation restrictions, environmental, health, and safety.

By way of example, laws and regulations related to cannabis in United States is listed under Schedule 1 of the Drug Enforcement Administration (DEA) as defined under the United States Controlled Substances Act even though there are 20 states have legalized medical marijuana and eight states legalized for recreational use.

Compliance with these laws, regulations and similar requirements may be onerous and expensive, and they may be inconsistent from jurisdiction to jurisdiction, further increasing the cost of compliance and doing business. Any such costs, which may rise in the future as a result of changes in these laws and regulations or in their interpretation could individually or in the aggregate make the Company’s products and services less attractive to the Company’s customers, delay the introduction of new products in one or more regions, or cause the Company to change or limit its business practices. The Company has implemented policies and procedures designed to ensure compliance with applicable laws and regulations, but there can be no assurance that the Company’s employees, contractors, or agents will not violate such laws and regulations or the Company’s policies and procedures.

Risk related to Liquidity and Capital Resources: Although our financial statements have been prepared on a going concern basis, we must raise additional capital before September 30, 2017 to fund our operations in order to continue as a going concern.

Turner, Stone & Company, L.L.P., our independent registered public accounting firm for the fiscal year ended December 31, 2016, has included an explanatory paragraph in their opinion that accompanies our audited financial statements as of and for the year ended December 31, 2016, indicating that our current liquidity position raises substantial doubt about our ability to continue as a going concern. If we are unable to improve our liquidity position we may not be able to continue as a going concern. The accompany consolidated financial statements do not include any adjustments that might result if we are unable to continue as a going concern and, therefore, be required to realize our assets and discharge our liabilities other than in the normal course of business which could cause investors to suffer the loss of all or a substantial portion of their investment.

We anticipate that our principal sources of liquidity will only be sufficient to fund our activities needs through September 30, 2017. In order to have sufficient cash to fund our operations beyond September 30, 2017, we will need to raise additional equity or debt capital by September 30, 2017 in order to continue as a going concern and we cannot provide any assurance that we will be successful in doing so.

Our stockholders are subject to significant dilution upon the occurrence of certain events which could result in a decrease in our stock price.

As of September 30, 2017, we had approximately 1.906 billion shares of our common stock reserved or designated for future issuance upon conversion of outstanding convertible promissory notes. Further, we may from time to time make an offer to our debtors or consultants to exchange their outstanding debts or services for shares of our common stock. Any future issuance of common shares will have a further dilutive effect on our existing stockholders and could result in a decrease in our stock prices.

Investment in new business strategies and acquisitions could disrupt the Company’s ongoing business and present risks not originally contemplated.

The Company has invested, and in the future may invest, in new business strategies or acquisitions. Such endeavors may involve significant risks and uncertainties, including distraction of management from current operations, greater than expected liabilities and expenses, inadequate return of capital, and unidentified issues not discovered in the Company’s due diligence. These new ventures are inherently risky and may not be successful.

The Company’s stock price is subject to volatility.

The Company’s stock continues to experience substantial price volatility. Additionally, the Company, the medical cannabis industry, and the stock market as a whole have experienced extreme stock price and volume fluctuations that have affected stock prices in ways that may have been unrelated to these companies’ operating performance.

The Company’s ability to raise additional capital to fund operations

The Company is required to raise additional funds to acquire research and growing facilities, and to cover cost of operations. We intend to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming or as to the terms of any such financings.

ITEM 2. LEGAL PROCEEDINGS

None.

ITEM 3. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended September 30, 2017, we have issued securities using exemptions available under the Securities Act of 1933:

As set out below, we have issued securities in exchange for services:

On February 16, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock to a consultant with a fair market value of $700,000 for legal and general consulting services under a consulting agreement dated January 13, 2017.

On February 16, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.05 and a fair market value of $700,000 to a consultant under a consulting agreement dated January 13, 2017.

On February 28, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.04 and a fair market value of $815,000 to Alfredo Dupetit-Bernardi, President/CEO of Cannabis Science Europe GmbH under an Option Agreement dated January 24, 2017.

On March 2, 2017, the Company issued 3,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $238,500 for consulting services under a consulting agreement dated March 2, 2017.

On March 27, 2017, the Company issued 15,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.075 and a fair market value of $1,140,000 to a consultant under an Option Agreement dated March 27, 2017. On September 29 2017, by mutual agreement, the Company and the Consultant agreed to cancel the 15,000,000 shares issued and these shares are to be returned to treasury for cancellation.

On May 17, 2017, the Company issued 1,500,000 shares of R144 restricted common stock to a consultant with a fair market value of $93,000 for consulting services pursuant to a three-month Marketing agreement.

On August 10, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.03 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement.

ITEM 4. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 5. MINE SAFETY DISCLOSURES

N/A

ITEM 6. OTHER INFORMATION

See Financial Statement Notes 4 in regards to stock compensation for officers and directors.

ITEM 7. EXHIBITS

Exhibit No.	Document Description	Filed Herewith (X) Incorporated by ref (I)

31.1	Certification by Raymond C. Dabney, Chief Executive Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
31.2	Certification by Benjamin Tam, Chief Financial Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
99.1	Promissory Notes	X
EX-101.INS	XBRL Instance Document	X
EX-101.SCH	XBRL Taxonomy Extension Schema	X
EX-101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
EX-101.LAB	XBRL Taxonomy Extension Label Linkbase	X
EX-101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
EX-101.DEF	XBRL Taxonomy Extension Definition Linkbase	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CANNABIS SCIENCE INC.


Date: November 20, 2017	/s/ Raymond C. Dabney
		Raymond C. Dabney
		Chief Executive Officer


Date: November 20, 2017	/s/ Benjamin Tam
		Benjamin Tam
		Chief Financial Officer

EX-31.1 2 exhibit31-1.htm EXHIBIT-31.1

Exhibit 31.1

Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of
the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002

I, Raymond C. Dabney, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Cannabis Science, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the Registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the period covered by the quarter report that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting.

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

	By: /s/Raymond C. Dabney
	Raymond C. Dabney
	Chief Executive Officer

November 20, 2017

EX-31.2 3 exhibit31-2.htm EXHIBIT-31.2

Exhibit 31.2

Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the
Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002

I, Benjamin Tam, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Cannabis Science, Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the Registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the period covered by the quarter report that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting.

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

	By: /s/Benjamin Tam
	Benjamin Tam
	Chief Financial Officer, Principal Accounting Officer

November 20, 2017

EX-32.1 4 exhibit32-1.htm EXHIBIT-32.1

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Cannabis Science., (the “Company”) on Form 10-Q for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raymond C. Dabney, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By: /s/Raymond C. Dabney
	Raymond C. Dabney
	Chief Executive Officer

November 20, 2017

EX-32.2 5 exhibit32-2.htm EXHIBIT-32.2

Exhibit 32.2

Certification Pursuant to18 U.S.C. Section 1350 as Adopted Pursuant to

Section 906of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Cannabis Science, Inc., (the “Company”) on Form 10-Q for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Benjamin Tam, Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By: /s/ Benjamin Tam
	Benjamin Tam
	Chief Financial Officer, Principal Accounting Officer

November 20, 2017

EX-101.INS 6 cbis-20170930.xml XBRL INSTANCE FILE 0001024626 2017-01-01 2017-09-30 0001024626 2016-12-31 0001024626 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001024626 CBIS:IntellectualPropertyAndGoodwillMember 2016-12-31 0001024626 CBIS:IntellectualPropertyAndGoodwillMember 2017-09-30 0001024626 us-gaap:PresidentMember 2017-01-01 2017-09-30 0001024626 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001024626 us-gaap:CommonClassAMember 2016-12-31 0001024626 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2017-09-30 0001024626 us-gaap:ComputerEquipmentMember 2017-09-30 0001024626 CBIS:PropertyFarmingRightsWithFortMcDermitAllotteesLandMember 2017-09-30 0001024626 CBIS:PropertyFarmingRightsWithWashoeTribalAllotmentLandsMember 2017-09-30 0001024626 CBIS:ManagementAndPayingAgentAgreementWithRMSMember 2017-09-30 0001024626 2015-12-31 0001024626 us-gaap:CommonStockMember 2016-12-31 0001024626 us-gaap:PreferredStockMember 2016-12-31 0001024626 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001024626 CBIS:PrepaidConsultingMember 2016-12-31 0001024626 us-gaap:RetainedEarningsMember 2016-12-31 0001024626 us-gaap:ReceivablesFromStockholderMember 2016-12-31 0001024626 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001024626 us-gaap:ParentMember 2016-12-31 0001024626 us-gaap:NoncontrollingInterestMember 2016-12-31 0001024626 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2017-09-30 0001024626 us-gaap:EquipmentMember 2017-09-30 0001024626 CBIS:PropertyFarmingRightsWithWashoeLandsMember 2017-09-30 0001024626 CBIS:SubTotalOfAllotmentForLandsMember 2017-09-30 0001024626 CBIS:SubTotalOfAllotmentForLandsMember 2016-12-31 0001024626 CBIS:PropertyFarmingRightsWithFortMcDermitAllotteesLandMember 2016-12-31 0001024626 CBIS:PropertyFarmingRightsWithWashoeTribalAllotmentLandsMember 2016-12-31 0001024626 CBIS:PropertyFarmingRightsWithWashoeLandsMember 2016-12-31 0001024626 CBIS:ManagementAndPayingAgentAgreementWithRMSMember 2016-12-31 0001024626 CBIS:ChiefMedicalOfficerMember 2017-01-01 2017-09-30 0001024626 CBIS:PropertyFarmingRightsWithWinnemuccaTribalMBSLandsMember 2017-09-30 0001024626 CBIS:PropertyFarmingRightsWithWinnemuccaTribalMBSLandsMember 2016-12-31 0001024626 2017-09-30 0001024626 2017-10-16 0001024626 us-gaap:SeriesAPreferredStockMember 2017-09-30 0001024626 us-gaap:CommonClassAMember 2017-09-30 0001024626 2016-01-01 2016-09-30 0001024626 2017-07-01 2017-09-30 0001024626 2016-07-01 2016-09-30 0001024626 2016-09-30 0001024626 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001024626 us-gaap:CommonStockMember 2017-09-30 0001024626 us-gaap:PreferredStockMember 2017-09-30 0001024626 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001024626 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001024626 CBIS:PrepaidConsultingMember 2017-01-01 2017-09-30 0001024626 CBIS:PrepaidConsultingMember 2017-09-30 0001024626 us-gaap:ReceivablesFromStockholderMember 2017-01-01 2017-09-30 0001024626 us-gaap:ReceivablesFromStockholderMember 2017-09-30 0001024626 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001024626 us-gaap:RetainedEarningsMember 2017-09-30 0001024626 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-09-30 0001024626 us-gaap:AccumulatedTranslationAdjustmentMember 2017-09-30 0001024626 us-gaap:ParentMember 2017-01-01 2017-09-30 0001024626 us-gaap:ParentMember 2017-09-30 0001024626 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-09-30 0001024626 us-gaap:NoncontrollingInterestMember 2017-09-30 0001024626 us-gaap:SubsidiariesMember 2012-12-31 0001024626 CBIS:MichiganGreenTechnologiesLLCMember 2014-08-06 0001024626 CBIS:MichiganGreenTechnologiesLLCMember 2015-02-20 0001024626 CBIS:MichiganGreenTechnologiesLLCMember 2015-02-19 2015-02-20 0001024626 CBIS:AssetAcquisitionOfEquiPharmLLCMember 2015-05-05 2015-05-06 0001024626 us-gaap:SubsidiariesMember 2017-02-02 0001024626 us-gaap:SubsidiariesMember CBIS:SharePurchaseAgreementMember 2017-02-01 2017-02-02 0001024626 us-gaap:SubsidiariesMember CBIS:SharePurchaseAgreementMember currency:EUR 2017-05-09 2017-05-10 0001024626 us-gaap:SubsidiariesMember CBIS:SharePurchaseAgreementMember 2017-05-09 2017-05-10 0001024626 us-gaap:SubsidiariesMember CBIS:SharePurchaseAgreementMember 2017-05-10 0001024626 CBIS:AssetPurchaseAgreementMember 2017-03-26 2017-03-27 0001024626 us-gaap:ChiefExecutiveOfficerMember 2017-09-30 0001024626 us-gaap:ChiefExecutiveOfficerMember 2016-12-31 0001024626 us-gaap:DirectorMember 2017-09-30 0001024626 us-gaap:DirectorMember 2016-12-31 0001024626 us-gaap:ChiefOperatingOfficerMember 2017-09-30 0001024626 us-gaap:ChiefOperatingOfficerMember 2016-12-31 0001024626 CBIS:ChiefFinancialOfficerTwoMember us-gaap:LoansPayableMember 2017-09-30 0001024626 CBIS:ChiefFinancialOfficerTwoMember us-gaap:LoansPayableMember 2016-12-31 0001024626 CBIS:ChiefFinancialOfficerTwoMember us-gaap:LoansPayableMember 2017-01-01 2017-09-30 0001024626 CBIS:ChiefFinancialOfficerTwoMember us-gaap:LoansPayableMember 2016-01-01 2016-12-31 0001024626 CBIS:ChiefExecutiveOfficerTwoMember 2017-09-30 0001024626 CBIS:ChiefExecutiveOfficerTwoMember 2016-12-31 0001024626 CBIS:ChiefExecutiveOfficerTwoMember 2017-01-01 2017-09-30 0001024626 CBIS:ChiefExecutiveOfficerTwoMember 2016-01-01 2016-12-31 0001024626 CBIS:ChiefExecutiveOfficerTwoMember 2015-07-01 2015-09-30 0001024626 CBIS:ShareholderMember us-gaap:LoansPayableMember 2017-09-30 0001024626 CBIS:ShareholderMember us-gaap:LoansPayableMember 2016-12-31 0001024626 CBIS:ShareholderMember us-gaap:LoansPayableMember 2017-01-01 2017-09-30 0001024626 CBIS:ShareholderMember us-gaap:LoansPayableMember 2016-01-01 2016-12-31 0001024626 CBIS:ShareholderOneMember us-gaap:LoansPayableMember 2017-09-30 0001024626 CBIS:ShareholderOneMember us-gaap:LoansPayableMember 2016-12-31 0001024626 CBIS:ShareholderOneMember us-gaap:LoansPayableMember 2017-01-01 2017-09-30 0001024626 CBIS:ShareholderOneMember us-gaap:LoansPayableMember 2016-01-01 2016-12-31 0001024626 CBIS:ChiefExecutiveOfficerOneMember us-gaap:LoansPayableMember 2017-09-30 0001024626 CBIS:ChiefExecutiveOfficerOneMember us-gaap:LoansPayableMember 2016-12-31 0001024626 CBIS:DirectorOneMember 2017-09-30 0001024626 CBIS:DirectorOneMember 2016-12-31 0001024626 CBIS:FormerChiefExecutiveOfficerMember 2017-09-30 0001024626 CBIS:FormerChiefExecutiveOfficerMember 2016-12-31 0001024626 CBIS:ShareholderTwoMember us-gaap:LoansPayableMember 2017-09-30 0001024626 CBIS:ShareholderTwoMember us-gaap:LoansPayableMember 2016-12-31 0001024626 CBIS:ShareholderTwoMember us-gaap:LoansPayableMember 2017-01-01 2017-09-30 0001024626 CBIS:ShareholderTwoMember us-gaap:LoansPayableMember 2016-01-01 2016-12-31 0001024626 CBIS:ShareholderThreeMember us-gaap:LoansPayableMember 2017-09-30 0001024626 CBIS:ShareholderThreeMember us-gaap:LoansPayableMember 2016-12-31 0001024626 CBIS:ShareholderThreeMember us-gaap:LoansPayableMember 2017-01-01 2017-09-30 0001024626 CBIS:ShareholderThreeMember us-gaap:LoansPayableMember 2016-01-01 2016-12-31 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2017-09-30 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2012-12-12 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2013-02-08 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember CBIS:AssetPurchaseAgreementMember 2017-01-01 2017-09-30 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2017-01-01 2017-09-30 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2016-12-31 0001024626 CBIS:ChiefExecutiveOfficerFourMember us-gaap:ConvertibleNotesPayableMember 2017-09-30 0001024626 CBIS:ChiefExecutiveOfficerFourMember us-gaap:ConvertibleNotesPayableMember 2016-12-31 0001024626 CBIS:ChiefExecutiveOfficerThreeMember 2017-07-01 2017-07-02 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2014-11-05 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2016-01-01 2016-12-31 0001024626 us-gaap:ChiefExecutiveOfficerMember CBIS:EndocanCorporationMember 2017-09-30 0001024626 CBIS:EmbellaHoldingsLtdMember us-gaap:NotesPayableOtherPayablesMember 2017-09-30 0001024626 CBIS:EmbellaHoldingsLtdMember us-gaap:NotesPayableOtherPayablesMember 2016-12-31 0001024626 CBIS:EmbellaHoldingsLtdMember us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-09-30 0001024626 CBIS:EmbellaHoldingsLtdMember us-gaap:NotesPayableOtherPayablesMember 2016-01-01 2016-12-31 0001024626 CBIS:IntrinsicCapitalCorpMember us-gaap:NotesPayableOtherPayablesMember 2017-09-30 0001024626 CBIS:IntrinsicCapitalCorpMember us-gaap:NotesPayableOtherPayablesMember 2016-12-31 0001024626 CBIS:IntrinsicCapitalCorpMember us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-09-30 0001024626 CBIS:IntrinsicCapitalCorpMember us-gaap:NotesPayableOtherPayablesMember 2016-01-01 2016-12-31 0001024626 CBIS:ChiefFinancialOfficerTwoMember us-gaap:LoansPayableMember CBIS:MichiganGreenTechnologiesLLCMember 2015-01-01 2015-03-07 0001024626 CBIS:ChiefFinancialOfficerTwoMember us-gaap:LoansPayableMember CBIS:MichiganGreenTechnologiesLLCMember 2015-03-07 0001024626 CBIS:ChiefExecutiveOfficerOneMember us-gaap:SeriesAPreferredStockMember 2014-07-24 2014-07-25 0001024626 CBIS:NotePayableOtherPayableOneMember 2017-09-30 0001024626 CBIS:NotePayableOtherPayableOneMember 2016-12-31 0001024626 CBIS:NotePayableOtherPayableOneMember 2017-01-01 2017-09-30 0001024626 CBIS:NotePayableOtherPayableOneMember 2016-01-01 2016-12-31 0001024626 CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2016-08-10 0001024626 CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2016-08-09 2016-08-10 0001024626 us-gaap:RestrictedStockMember CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2016-08-09 2017-09-30 0001024626 us-gaap:RestrictedStockMember CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2016-12-31 0001024626 CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2016-08-09 2016-12-31 0001024626 CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2017-09-30 0001024626 CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2016-12-31 0001024626 CBIS:NotePayableOtherPayableAugustTenTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-09-30 0001024626 CBIS:NotePayableOtherPayableOctoberOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2016-10-01 0001024626 CBIS:NotePayableOtherPayableOctoberOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2017-07-01 2017-09-30 0001024626 CBIS:NotePayableOtherPayableOctoberOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2017-09-30 0001024626 CBIS:NotePayableOtherPayableOctoberOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2016-12-31 0001024626 CBIS:NotePayableOtherPayableDecemberThirtyOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2016-12-31 0001024626 CBIS:NotePayableOtherPayableDecemberThirtyOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2017-09-30 0001024626 CBIS:NotePayableOtherPayableDecemberThirtyOneTwoThousandSixteenMember CBIS:ChiefExecutiveOfficerFourMember 2017-01-01 2017-09-30 0001024626 CBIS:NotePayableOtherPayableMayThirtyOneTwoThousandSeventeedMember CBIS:ChiefExecutiveOfficerFourMember 2017-05-31 0001024626 CBIS:NotePayableOtherPayableMayThirtyOneTwoThousandSeventeedMember CBIS:ChiefExecutiveOfficerFourMember 2017-09-30 0001024626 CBIS:NotePayableOtherPayableMayThirtyOneTwoThousandSeventeedMember CBIS:ChiefExecutiveOfficerFourMember 2016-12-31 0001024626 CBIS:NotePayableOtherPayableMayThirtyOneTwoThousandSeventeedMember CBIS:ChiefExecutiveOfficerFourMember 2017-01-01 2017-09-30 0001024626 us-gaap:CommonClassAMember 2017-01-01 2017-09-30 0001024626 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-09-30 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementMember 2017-01-01 2017-09-30 0001024626 us-gaap:RestrictedStockMember CBIS:ConsultingAgreementDatedJanuaryThirteenTwoThousandSeventeenMember CBIS:ConsultantMember 2017-02-15 2017-02-16 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementDatedJanuaryThirteenTwoThousandSeventeenMember CBIS:ConsultantMember 2017-02-15 2017-02-16 0001024626 us-gaap:RestrictedStockMember CBIS:TwoYearConsultingAgreementMember CBIS:ConsultantMember 2017-03-01 2017-03-02 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementDatedMarchSevenTwoThousandSeventeenMember CBIS:TwoThousandSixteenEquityAwardPlanBMember 2017-03-06 2017-03-07 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementDatedJulySixTwoThousandSixteenMember CBIS:TwoThousandSixteenEquityAwardPlanBMember 2017-03-12 2017-03-13 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementDatedAprilTwentyNineTwoThousandFifteenMember CBIS:TwoThousandSixteenEquityAwardPlanBMember 2017-03-12 2017-03-13 0001024626 us-gaap:RestrictedStockMember CBIS:OneYearConsultingAgreementMember CBIS:ConsultantMember 2017-05-04 2017-05-05 0001024626 us-gaap:RestrictedStockMember CBIS:ThreeMonthMarketingAgreementMember CBIS:ConsultantMember 2017-05-16 2017-05-17 0001024626 us-gaap:CommonStockMember CBIS:TwoYearConsultingAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember 2017-08-09 2017-08-10 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementDatedAugustTenTwoThousandSeventeenMember CBIS:TwoThousandSixteenEquityAwardPlanBMember 2017-08-30 2017-08-31 0001024626 us-gaap:RestrictedStockMember CBIS:ConsultingAgreementMember CBIS:TwoConsultantsMember 2017-09-28 2017-09-30 0001024626 us-gaap:CommonStockMember CBIS:ConsultingAgreementMember 2017-09-28 2017-09-30 0001024626 us-gaap:StockOptionMember us-gaap:VicePresidentMember 2011-09-15 2011-09-16 0001024626 us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ConsultantMember 2017-01-12 2017-01-13 0001024626 us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:CEOOfCannabisScienceEuropeGmbHMember 2017-01-23 2017-01-24 0001024626 us-gaap:CommonStockMember CBIS:FiveYearConsultingAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ConsultantMember 2017-03-26 2017-03-27 0001024626 us-gaap:CommonStockMember CBIS:FiveYearConsultingAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ConsultantMember 2017-09-28 2017-09-29 0001024626 us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ChiefMedicalOfficerMember 2017-04-17 2017-04-18 0001024626 us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ConsultantMember 2017-08-01 2017-08-02 0001024626 us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ConsultantMember 2017-08-09 2017-08-10 0001024626 us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBOneMember CBIS:ConsultantMember 2017-08-09 2017-08-10 0001024626 CBIS:JointVentureLicenseAgreementMember 2016-03-23 2016-03-24 0001024626 CBIS:MasterFacilitatorAgreementMember 2016-10-23 2016-10-24 0001024626 CBIS:ExclusiveMasterFacilitatorAgreementMember 2016-11-11 2016-11-12 0001024626 CBIS:SixExclusiveMasterFacilitatorAgreementMember 2016-12-17 2016-12-18 0001024626 CBIS:TwoExclusiveMasterFacilitatorAgreementMember 2016-12-20 2016-12-21 0001024626 CBIS:ExclusiveMasterFacilitatorAgreementWithWinnemuccaTribalMBSMember 2017-05-16 2017-05-18 0001024626 us-gaap:SubsequentEventMember CBIS:ExclusiveMasterFacilitatorAgreementWithWinnemuccaTribalMBSMember 2017-10-09 0001024626 us-gaap:ComputerEquipmentMember 2017-01-01 2017-09-30 0001024626 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2017-01-01 2017-09-30 0001024626 us-gaap:EquipmentMember 2017-01-01 2017-09-30 0001024626 us-gaap:AutomobilesMember 2017-01-01 2017-09-30 0001024626 us-gaap:ManagementMember CBIS:EndocanCorporationMember 2014-11-04 2014-11-05 0001024626 us-gaap:IntellectualPropertyMember 2017-01-01 2017-09-30 0001024626 us-gaap:GoodwillMember 2017-01-01 2017-09-30 0001024626 us-gaap:SubsequentEventMember us-gaap:CommonStockMember CBIS:OptionAgreementMember CBIS:TwoThousandSixteenEquityAwardPlanBMember CBIS:ConsultantMember 2017-10-15 2017-10-17 0001024626 us-gaap:SubsequentEventMember CBIS:SanJoaquinCountyAndDEAMember 2017-10-26 2017-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR CANNABIS SCIENCE, INC. 0001024626 10-Q 2017-09-30 false --12-31 No No Yes Smaller Reporting Company Q3 2017

172000

139750

1010000

415000

595000

660299

488299

520549

4723

20252

29879

4904

29879

75000000

60000000

10000000

15000000

10000000

20000000

808514

268448

808514

268448

-10153166

-12033272

-3512680

-6955569

-10197577

44411

5000

6482

330026

11482

341508

5000

5971

9167

10971

20138

511

320859

511

321370

170688

751726

945121

50000

640000

85000

890000

200000

975000

-1786836

1000

2350356

1000

136963520

-1705659

-138137771

-655000

-11495

-1195049

-591787

-3156584

1000

2521006

1000

148164025

-3674296

-1275774

-148335348

-9821

-2609208

-547376

1506745

1758655

1108896

231260

1758655

1506745

670407

538425

627066

52000

52500

11871

101882

3165

191344

106186

93885

447

95909

23378

20502

884465

1267745

229180

14200

30000

52500

105000

30000

272644

202477

247500

1000000

2350355296

2521005296

11700000

1700000

0.069

0.041

170688

42490

576520

244

90000

130500

141750

30000

2521095296 2551805296

75000000

65214

4263602

5237434

177698

510018

300000

856269

773950

2476766

2080850

1280396

472132

102993

151675

36001

22715

2476766

1000

2080850

1000

-591787

-547376

-1195049

1000

-2609208

1000

-11495

-9821

-138137771

-148335348

655000

1275774

1705659

3674296

136963520

148164025

2350356

2521006

1000

0.001

1000000

0.001

3000000000

100000000

3000000000

100000000

2350355296

2521005296

-10195903

-11954467

-3508299

-6955770

1674

392

3037

-201

1674

392

3037

-201

-10197577

-11954859

-3511336

-6955569

44411

-78413

-1344

-1093791

-902

-412456

-71250

-19500

-116250

1022541

902

392956

-9059375

-12032370

-3100224

-6955569

9062432

12037281

3101358

6956895

7855375

6082880

2720660

2301712

511345

265024

125513

6487

41672

57853

16345

19284

-971500

-4138645

-3550000

343590

254079

68501

58962

310450 267300 170339 48950

3057

4911

1134

1326

3245

3609

1183

1407

6302

8520

2317

2733

2426212256

1894510405

2468885731

2106170513

-303594

-50926

1674

392

650954

715724

1089226

632500

438272

295000

55000

438272

295855

82369

11871

52500

-330792

-31339

48611

50000

330026

766

244

17516

-625430

-735703

-88641

383280

812218

292681

411616

220000

48682

73739

1083

321

-438816

-11250

1909000 1138500

5368518

3825874

1022502

251910

533092

112500

125000

40000

169527

57853

-13286

-4173

332888

61971

29294

11045

5368518

1816732

4434500

1909000 3888500

271350

295000

1275774 2499 20000

88641

29852

110650000

5000000

10000000

3000000

15000000

10000000

15000000

7000000

15000000

25000000

30000000

3038226

60000

3599000

-620774

3038226

700000

815000

1140000

829000

465000

425000

610000

1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   A. Organization and General Description of Business   Cannabis Science, Inc.  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation.  On March 25, 2008 the Company changed its name to Gulf Onshore, Inc.  On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.     On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC Pink: CBIS.   Cannabis Science, Inc. is at the forefront of medical marijuana research and development.  The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.  In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.  The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 th and May 6 th, 2013, respectively, to pursue business opportunities in Europe and worldwide.  There are currently minimal operations in the subsidiaries.  Agreements and business disclosures are in process.   On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neuro behavioral Disorders."  The subject of the patent is development of cannabinoid-based formulations to treat a variety of neuro behavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.     B.  Basis of Presentation   These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars.  The Company’s fiscal year end is December 31.   Interim Financial Reporting   While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2016 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine-month periods ended September 30, 2017 and 2016. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2016 included in our Form 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.   The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the nine months ended September 30, 2017:   In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) in which the Company own 90% to operate joint-venture operations with Dupetit Natural Products Ltd.  The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012.  No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany.   On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations.  The Company has commenced some operating activities with cultivation in Spain and product development in 2014.  Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV, MJR BV and Cannabis Agency BV, all are Netherlands registered companies.   On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%.  As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT.   On May 6, 2015, the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. in the state of Tennessee and started the operation of distributing of existing and new line of products.   On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with JinvatorBioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. Jinvator developed a prototype called nanoGold-Test which is based on nano-particle technology for the detection of HIV in the early stage of infection. Patent has been submitted and pending for approval.The acquisition is pending on verification of key information.   On May 10, 2017, the Company paid €60,000, which has a US dollar equivalent of $65,214, to the principal shareholder of JinvatorBioMed GmbH (Jinvator) as deposit for the purchase of the 74.9% equity interest in Jinvator.   On March 27, 2017, the Company entered an agreement to acquire the Assets of AFA Research and Development, a California sole proprietorship of Aja Fonseca Arnold in the research and development of products based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.   For other accounting policies please refer to the Company’s 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017.   The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

2.  GOING CONCERN   The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern.  The Company reported an accumulated deficit of $148,335,348 and had a stockholders’ deficit of $3,156,584 as of September 30, 2017.   In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital.  At September 30, 2017, the Company had insufficient operating revenues and cash flow to meet its financial obligations.  There can be no assurance that management will be successful in implementing its plans.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.   We anticipate that we will have to raise additional capital to fund operations over the next 12 months.  To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities.  There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings.   Any future financing may involve substantial dilution to existing investors.  We had been relying on our common stock to pay third parties for services which has resulted in substantial dilution to existing investors.

3. FAIR VALUE MEASUREMENTS AND DISCLOSURES   ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

4.  RELATED PARTY TRANSACTIONS   At September 30, 2017, a total of $229,180 (December 31, 2016: $14,200) in Accrued Management Fees Payable was due to the Company’s CEO/Director, Raymond C. Dabney.   At September 30, 2017, a total Prepaid management fees of $30,000 (December 31, 2016: Prepaid $52,500) advanced to the Company’s Director, Mario Lap.   At September 30, 2017, a total of $105,000 (December 31, 2016: Prepaid $30,000) in Accrued Management Fees Payable was due to the Company’s COO/Director, Robert Kane.   At September 30, 2017, a total of $52,000 (December 31, 2016: $52,500) in loans payable was due to the Company’s CFO, Robert Kane, through his company, R Kane Holding Inc., secured by a non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.   At September 30, 2017, the Company owes $11,871 (December 31, 2016: $11,871) to Crown Baus Capital Corp., which advanced a total of $11,871 for payment of the Company’s expenses in July, August and September of 2015 with no interest and no security. Crown Baus Capital Corp. is a company controlled by Raymond C. Dabney.   As of September 30, 2017, the Company owes $101,882 (December 31, 2016: $101,882) in loan payable to a stockholder, Interstate 101 that is non-interest bearing and due on demand with no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.   At September 30, 2017, the Company owes $3,165 (December 31, 2016: $3,165) in loan payable to Castor Management Services, a shareholder of the Company, with no interest and no security and is due on demand. The loan originated on August 14, 2015 for expenses of the Company.     At September 30, 2017, a total of $191,344 (December 31, 2016: $191,344) in loans payable was due to Bogat Family Trust, of which Raymond Dabney the Company’s Director and President/CEO as trustee.   At September 30, 2017, $106,186 (December 31, 2016: $93,885) was due to MJR BV, owned by Mario Lap director and director and officer of EU subsidiaries.     At September 30, 2017, $447 (December 31, 2016: $447) was due to Robert Melamede, former CEO.   At September 30, 2017, a total of $95,909 (December 31, 2016: $23,378) in loans payable was due to Drue Young, a shareholder of the Company, with no interest and no security and is due on demand. The loan originated from January 11, 2016 to September 30, 2017 for expenses of the Company.   At September 30, 2017, a total of $20,502 (December 31, 2016: $20,502) in loans payable was due to Intrinsic Venture Corp., a shareholder of the Company, with no interest and no security and is due on demand. The loan originated from April 22, 2011 to December 31, 2014.   At September 30, 2017, the Company held 7,500,000 common shares in the OmniCanna Health Solutions, Inc. (prior to April 24, 2014, the name was Endocan Corporation) (OTCBB: ENDO) (“OmniCanna”) representing approximately 2.89% of the issued and outstanding shares of OmniCanna, of which 5,000,000 common shares were acquired at a fair market value of $150,000 or $0.03 per share on December 12, 2012 and 2,500,000 common shares were acquired at a fair market value of $262,250 or $0.1049 per share on February 8, 2013.  The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the Dupetit Natural Products GmbH joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement.  The value of the shares at September 30, 2017 was determined to be $0.0155 per share or $116,250 with the Company recording unrealized loss under the Equity Investee rules for the nine months ended September 30, 2017 and the value of the shares at December 31, 2016 was determined to be $0.025 per share or $187,500.   Convertible Notes Payable to Royalty Management Services Corp., a company owned by a family member of Mr. Raymond C. Dabney, CEO/Director of the Company, entered into a management agreement with the Company on September 15, 2015 for accounting services, websites development and maintenance, office management, management and payments for travel, promotion and entertainments, shareholders communications and payment services totaled $797,518 and $860,790 at September 30, 2017 and December 31, 2016 respectively. See Note 5.   On July 2, 2017, the Company donated $40,000 to Constituency For Africa, a charitable organization found in United States for the people in Africa, of which Mr. Raymond C. Dabney is a Board member.   On November 5, 2014, the Company transitioned to equity method investee accounting for the OmniCanna shares pursuant to ASC 323 recording $247,500 as the fair value of the shares to its equity method investee account.  On December 31, 2016, the Company recorded an impairment on the equity method investee account of $144,000 in relation to the shares.  Robert Kane, COO and director of the Company is also the COO and a director of OmniCanna. Benjamin Tam, CFO and a director is also a director and CFO of Omnicanna.  Raymond Dabney, CEO has 10.78% equity interest in Omniccanna Health Solutions, Inc. as of September 30, 2017.   For the nine months ended September 30, 2017, the following related party stock-based compensation was recorded:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid">Related Party</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; border-bottom: Black 1pt solid">Position</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left; padding-left: 0; vertical-align: top">Alfredo Bernardi Dupetit</td><td style="width: 8%"> </td> <td style="width: 28%; text-align: left; padding-left: 0">President & CEO of Cannabis Science Europe GmbH</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left; vertical-align: top">$</td><td style="width: 26%; text-align: right; vertical-align: top">415,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0">Dr. Allen Herman</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0">Chief Medical Officer</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">595,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 14.25pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 13.5pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,010,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   1 Including compensation to entities beneficially owned/control by the related parties   See Note 6 -Equity Transactions for details of stock issuances to director and officers for services rendered.   Mario Lap, a director of the Company and director and officer of its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MJR BV, MLS Lap BV and Cannabis Agency BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time.  The Company anticipates having the Spanish subsidiary setup soon at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company.   Alfredo Dupetit-Bernardi, International Product Development and President & CEO of Cannabis Science Europe GmbH, is conducting product development through the purchase of cannabis products from his personal company, Dupetit Natural Products GmbH.   On August 10, 2016, a total of $975,407 in Management Fees Payable accumulated from February 2012 to September 30, 2016 was converted into a two-year Convertible Promissory Note to Raymond C. Dabney, CEO/Director of the Company. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company paid $55,000 in expenses for Mr. Dabney in 2016. The balance of the Convertible Promissory Note as of September 30, 2017 was $670,407 (December 31, 2016: $670,407).   Notes payable to Embella Holdings Ltd. totaled $1,108,896 and $1,108,896 at September 30, 2017 and December 31, 2016, respectively.  As of September 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. See Note 5.   Notes payable to Intrinsic Capital Corp. totaled $231,260 and $231,260 at September 30, 2017 and December 31, 2016, respectively. See Note 5.    Between January 1, 2015 to March 7, 2015, R. Kane Holding Inc., a company owned by Mr. Robert Kane, director and CFO, had advanced $52,500 into Michigan Green Technologies, LLC, which is 50.1% controlled by the Company as Loan Payable to R. Kane Holding Inc.   On July 25, 2014, Bogat Family Trust, with Raymond Dabney as trustee, representing a majority of Series A preferred stockholders, signed a resolution to approve an amendment to the certificate of designation preferences and rights for Series A preferred shares. Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters.  No common stockholders voted on this amendment.

5.  NOTES PAYABLE   As of September 30, 2017, a total of $1,758,655 (December 31, 2016: $1,506,745) of notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 2016. $1,340,156 of the Promissory notes were in default on September 30, 2017. As of September 30, 2017, a total of $1,467,925 convertible promissory notes (December 31, 2016: $1,531,197) are convertible to common stock of the Company. All promissory notes are unsecured.   Notes payable to Embella Holdings Ltd that are non-interest bearing totaled $1,108,896 and $1,108,896 at September 30, 2017 and December 31, 2016, respectively.  As of September 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. The note payable is classified with notes payable to stockholders.   Notes payable to Intrinsic Capital Corp. that are non-interest bearing totaled $231,260 and $231,260 at September 30, 2017 and December 31, 2016, respectively. As of September 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. The note payable is classified with notes payable to stockholders.   On August 10, 2016, a total of $975,407 in Management Fees Payable accumulated from February 2012 to June 30, 2016 was converted into a two-year Convertible Promissory Note to Raymond C. Dabney, CEO/Director of the Company. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and will amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company paid $55,000 in expenses for Mr. Dabney in 2016. The balance of the Convertible Promissory Note as of September 30, 2017 was $670,407 (December 31, 2016: $670,407). In the nine months ended September 30, 2017, the Company recorded $251,910 as interest for the amortization, conversion and payment. The note payable is classified with notes payable to stockholders.   On October 1, 2016, a total of $710,790 in Accounts Payable for management fees accumulated from January 2016 to October 1, 2016 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp., a related party. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The Company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The Company paid $438,272 during the period from July 2, 2017 to September 30, 2017 to Royalty Management Services Corp., a related party. The balance of the Convertible Promissory Note as of September 30, 2017 was $272,518 (December 31, 2016: $710,790). In the nine months ended September 30, 2017 the Company recorded $533,092 as interest for the amortization, conversion and payment.   On December 31, 2016, $150,000 in Accounts Payable for management fees accumulated from November 1, 2016 to December 31, 2016 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp., a related party. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The balance of the Convertible Promissory Note as of September 30, 2017 was $150,000 (December 31, 2016: $150,000). In the nine months ended September 30, 2017 the Company recorded $112,500 as interest for the amortization, conversion and payment.   On May 31, 2017, $375,000 in Accounts Payable for management fees accumulated from January 1, 2017 to May 31, 2017 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp., a related party. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The balance of the Convertible Promissory Note as of September 30, 2017 was $375,000 (December 31, 2016: $0). In the nine months ended September 30, 2017 the Company recorded $125,000 as interest for the amortization, conversion and payment.

6.  EQUITY TRANSACTIONS   The Company is authorized to issue 3,000,000,000 shares of common stock with a par value of $0.001 per share.  These shares have full voting rights.  There were 2,521,005,296 and 2,350,355,296 issued and outstanding as of September 30, 2017 and December 31, 2016, respectively. The current authorized common stock of 3,000,000,000 shares will not be sufficient if and when the debt holders of convertible promissory notes elect to convert the debts into common shares. The Company intends to file for an increase in the number shares in authorized common stock once the required updated financial reporting have been filed with the Securities Exchange Commission.   The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share.  These shares have 10 votes per share.  There were 0 issued and outstanding as of September 30, 2017 and December 31, 2016.   The Company is also authorized to issue 1,000,000 shares of preferred stock.  These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State.  There were 1,000,000 issued and outstanding as of September 30, 2017 and December 31, 2016.   As set out below, we have issued securities in exchange for services, properties and for debt, using exemptions available under the Securities Act of 1933.   During the nine months ended September 30, 2017, the Company issued 121,500,000 shares of common stock and cancelled 10,850,000 pending to be issued shares of common stock for services under various executive and consulting agreements as follows:   On February 16, 2017, the Company issued 5,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $350,000 for legal and general consulting services under a consulting agreement dated January 13, 2017.   On February 16, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock to a consultant with a fair market value of $700,000 for legal and general consulting services pursuant to a consulting agreement dated January 13, 2017.   On March 2, 2017, the Company issued 3,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $271,500 for consulting services pursuant to a two-year consulting agreement.   On March 7, 2017, the Company issued 15,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,270,500 for consulting services under a consulting agreement dated March 7, 2017.   On March 13, 2017, the Company issued 10,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $883,000 for consulting services pursuant to a consulting agreement dated July 6 2016.   On March 13, 2017, the Company issued 15,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,324,500 for consulting services pursuant to a consulting agreement dated April 29, 2015.   On May 5, 2017, the Company issued 7,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $469,000 for consulting services pursuant to a one year consulting agreement.   On May 17, 2017, the Company issued 1,500,000 shares of R144 restricted common stock to a consultant with a fair market value of $93,600 for consulting services pursuant to a three-month Marketing agreement.   On August 10, 2017, the Company issued 25,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,062,500 for consulting services pursuant to a two-year consulting agreement.   On August 31, 2017, the Company issued 30,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,392,000 for bonus to a consultant pursuant to a two-year consulting agreement dated August 10, 2017.   On September 30, 2017, the Company cancelled 3,500,000 shares of R144 restricted common stock, which were pending to be issued since 2015 to two consultants shares with a total fair market value of $107,750 based on the date of the Consultant Agreements, for non-performance of services.   On September 30, 2017, the company cancelled 7,350,000 shares S-8 registered free trading common stock, which were pending to be issued from 2014 to 2016 with a total fair market value of $371,695 based on the date of the Consultant Agreement, for non-performance of services.   Stock Options:   The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">(i)</td><td style="font: 10pt Times New Roman, Times, Serif">the option to purchase 100,000 common shares at ten cents ($0.10) per share;</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">(ii)</td><td style="font: 10pt Times New Roman, Times, Serif">the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and</td></tr></table>     <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">(iii)</td><td style="font: 10pt Times New Roman, Times, Serif">the option to purchase 100,000 common shares at twenty cents ($0.20) per share;</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">(iv)</td><td style="font: 10pt Times New Roman, Times, Serif">the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.</td></tr></table>   On January 13, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.05 and a fair market value of $700,000 to a consultant pursuant to a consulting agreement.   On January 24, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.04 and a fair market value of $815,000 to Alfredo Dupetit-Bernardi, President/CEO of Cannabis Science Europe GmbH.   On March 27, 2017, the Company issued 15,000,000 shares S-8 registered free-trading common stock under the 2016 Equity Award Plan B with exercise price at $0.075 and a fair market value of $1,140,000 to a consultant pursuant to a five-year consulting agreement. On September 29 2017, by mutual agreement, the Company and the Consultant agreed to cancel the 15,000,000 shares issued and these shares are to be returned to treasury for cancellation.   On April 18, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 and a fair market value of $829,000 to Chief Medical Officer, Dr. Allen Herman.   On August 2, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.015 and a fair market value of $465,000 to a consultant pursuant to a consulting agreement.   On August 10, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement.   On August 10, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.03 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement.   A summary of the status of the Company’s option grants as of September 30, 2017 and the changes during the period then ended is presented below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-indent: 0; padding-left: 0">Outstanding December 31, 2016</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">11,700,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.069</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,000,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.010</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Outstanding September 30, 2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.041</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Options exercisable at September 30, 2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.041</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Shares issued under option agreement to be returned and cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.075</td><td style="text-align: left"> </td></tr> </table>    1,700,000 shares of these options at an average exercise price of $0.41 a share, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane. The weighted average fair value at date of grant for options during year ended September 30, 2017 was estimated using the Black-Scholes option valuation model with the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0; width: 56%">Average expected life in years for outstanding options</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">Years </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Average risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Average volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137.2697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">%</td><td style="text-align: left"> </td></tr></table>

7.  EQUIPMENT AND GREENHOUSE    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="text-align: center; vertical-align: bottom"> <td colspan="2" style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td><td style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td> <td colspan="3" style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none">Accumulated</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none">September 30, 2017</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none">December 31, 2016</td></tr> <tr style="text-align: center; vertical-align: bottom"> <td colspan="2" style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Cost</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Depletion</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Net Book Value</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Net Book Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Computer</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 16%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">6,482</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 16%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">5,971</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 15%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">511</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 15%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Software</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">5,000</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">5,000</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none; text-align: right"> </td><td style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">11,482</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">10,971</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">511</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Greenhouse</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">330,026</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">9,167</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">320,859</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">341,508</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">20,138</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">321,370</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr></table>

8. PROPERTY FARMING RIGHTS   On March 24, 2016, the Company entered a 15 years Joint Venture Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two initial payments of $50,000 for farming rights and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA.  Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products.  All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.   On October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is 40% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.    On November 12, 2016, the Company entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.    On December 18, 2016, the Company enter six (9) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.   On December 21, 2016, the Company enter two (2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.   On May 18, 2017, the Company entered an Exclusive Master Facilitator Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit Organics, LLC (FSO), American Education Consulting Group, Raymond C. Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to lease and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and retain 5% of net profit as master facilitator.The Company wrote off the operating capital in the amount of $212,000 for Winnemucca Lands inclusive of HRM Farm due to the illegal seizure of cultivated industrial hemp by San Joaquin County and Department of Enforcement Agency (DEA) on October 9, 2017. The Company has filed a suit against the San Joaquin County and DEA on October 27, 2017.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center">September 30, 2017</td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center">December 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Cost</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Accumulated Depletion</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: normal; text-transform: none; text-align: left">Property Farming Rights</td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">Fort McDermit Allottees Land</td> <td style="width: 2%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">50,000</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="width: 2%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">4,723</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="width: 2%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">45,277</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="width: 2%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">47,778</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left">Washoe Tribal Allotment Lands</td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">640,000</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">20,252</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">619,748</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">638,948</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt">Winnemucca Tribal MBS Lands</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">200,000</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">4,904</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">195,096</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">890,000</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">29,879</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">860,121</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">686,726</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt">Operating capital for Washoe Lands</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">85,000</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">—  </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">85,000</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">—  </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt">Total</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">975,000</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">29,879</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">945,121</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">686,726</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> </table>    All equipment is stated at cost.  Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized.  Depreciation is computed using the straight-line method over the estimated lives of the related assets, 2 years for computer, 2 years for software, 5 years for equipment and laboratory equipment and 3 years for automobile.   All property farm rights are amortized over the term of each respective agreements.

9.  EQUITY METHOD INVESTEE   On November 5, 2014, the Company accounted for its investment and loans in OmniCanna Health Solutions, Inc. (formerly Endocan Corporation) using the equity method pursuant to ASC 323 – Investments – Equity Method and Joint Ventures.  In accordance with ASC 323, when the Company does not have a controlling financial interest in an entity but exerts significant influence over the entity’s operating and financial policies, the Company accounts for its investment in accordance with the equity method of accounting. This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.   The accounting using the equity method is in conjunction with appointment of Raymond Dabney as CEO and director of the Company on November 5, 2014, in addition to Mr. Dabney being a controlling shareholder of the Company since September 2009 and a 10.78% equity interest in OmniCanna since June 2013. Benjamin Tam, CFO and director and Robert Kane, COO and director of the Company are also the CFO and director and COO and director of Omnicanna.  Therefore, the Company was deemed to have significant influence and control of OmniCanna Health Solutions, Inc.   On November 5, 2014, the Company recorded $247,500 in marketable securities and $85,277 (based on currency converted as of September 30, 2017) in loans to OmniCanna and to its equity method investee account in accordance with ASC 323.  An unrealized loss on the equity method account of $71,250 was recognized for the nine months ended September 30, 2017 in addition to a unrealized gain on the equity method investee account of $144,000 was recognized for the year ended December 31, 2016 in the value of Omnicanna marketable securities.

10. GOODWILL and INTANGIBLE ASSETS   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, 2017</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Intellectual assets, primarily intellectual property</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">660,299</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">660,299</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(520,549</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(488,299</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Impairment of Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(170,688</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(170,688</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">172,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for both intellectual assets and Goodwill).

11. PREPAID EXPENSES AND DEPOSITS HELD WITH RMS   On October 1, 2016, the Company entered a Paying Agent Agreement with Royalty Management Services Corp. (RMS) for holding funds and making payment for expenses and commitments of the Company. The Company has entered a Management Agreement with RMS since September 15, 2016 for management, investors’ and shareholders’ communications, website development, database management, accounting and management of all activities such as travel and conference. All the expenses related to the services for the Company are included as part of the management fees.    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, 2017</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Prepaid consulting expenses</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">130,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">141,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Prepaid Legal fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Prepaid rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Prepaid management fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Deposits held with RMS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576,520</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deposit for acquisition of Jinvator</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">65,214</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Prepaid expenses and Deposits held with RMS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,448</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">808,514</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

12. COMMITMENTS   The Company has lease commitments for its European operations under private companies, MLS Lap B.V. and MJR B.V. owned and controlled by Mario Lap, director of the Company and director and officer of EU subsidiaries. Negotiations are ongoing in regards to preparing finalized agreements between the Company and Mr. Lap’s companies.

13.  SUBSEQUENT EVENTS   On October 17, 2017, the Company issued 20,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.025 and a fair market value of $610,000 to a consultant.   On October 27, 2017, the Company filed a suit against San Joaquin County and DEA for illegal seizure of cultivated industrial hemp crops from HRM Farm in Winnemucca Tribal Land for return of the seized properties.

A. Organization and General Description of Business   Cannabis Science, Inc.  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation.  On March 25, 2008 the Company changed its name to Gulf Onshore, Inc.  On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.     On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC Pink: CBIS.   Cannabis Science, Inc. is at the forefront of medical marijuana research and development.  The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.  In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.  The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 th and May 6 th, 2013, respectively, to pursue business opportunities in Europe and worldwide.  There are currently minimal operations in the subsidiaries.  Agreements and business disclosures are in process.   On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neuro behavioral Disorders."  The subject of the patent is development of cannabinoid-based formulations to treat a variety of neuro behavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.

B.  Basis of Presentation   These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars.  The Company’s fiscal year end is December 31.   Interim Financial Reporting   While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2016 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine-month periods ended September 30, 2017 and 2016. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2016 included in our Form 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.   The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the nine months ended September 30, 2017:   In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) in which the Company own 90% to operate joint-venture operations with Dupetit Natural Products Ltd.  The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012.  No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany.   On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations.  The Company has commenced some operating activities with cultivation in Spain and product development in 2014.  Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV, MJR BV and Cannabis Agency BV, all are Netherlands registered companies.   On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%.  As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT.   On May 6, 2015, the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. in the state of Tennessee and started the operation of distributing of existing and new line of products.   On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with JinvatorBioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. Jinvator developed a prototype called nanoGold-Test which is based on nano-particle technology for the detection of HIV in the early stage of infection. Patent has been submitted and pending for approval.The acquisition is pending on verification of key information.   On May 10, 2017, the Company paid €60,000, which has a US dollar equivalent of $65,214, to the principal shareholder of JinvatorBioMed GmbH (Jinvator) as deposit for the purchase of the 74.9% equity interest in Jinvator.   On March 27, 2017, the Company entered an agreement to acquire the Assets of AFA Research and Development, a California sole proprietorship of Aja Fonseca Arnold in the research and development of products based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.   For other accounting policies please refer to the Company’s 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017.   The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

For the nine months ended September 30, 2017, the following related party stock-based compensation was recorded:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1pt solid">Related Party</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; border-bottom: Black 1pt solid">Position</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left; padding-left: 0; vertical-align: top">Alfredo Bernardi Dupetit</td><td style="width: 8%"> </td> <td style="width: 28%; text-align: left; padding-left: 0">President & CEO of Cannabis Science Europe GmbH</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left; vertical-align: top">$</td><td style="width: 26%; text-align: right; vertical-align: top">415,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0">Dr. Allen Herman</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0">Chief Medical Officer</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">595,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 14.25pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 13.5pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,010,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   1 Including compensation to entities beneficially owned/control by the related parties

A summary of the status of the Company’s option grants as of September 30, 2017 and the changes during the period then ended is presented below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Shares</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-indent: 0; padding-left: 0">Outstanding December 31, 2016</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">11,700,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.069</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.064</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,000,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.010</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Outstanding September 30, 2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.041</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Options exercisable at September 30, 2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.041</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Shares issued under option agreement to be returned and cancelled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.075</td><td style="text-align: left"> </td></tr></table>

The weighted average fair value at date of grant for options during year ended September 30, 2017 was estimated using the Black-Scholes option valuation model with the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0; width: 56%">Average expected life in years for outstanding options</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">Years </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Average risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Average volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137.2697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 0; padding-left: 0">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">%</td><td style="text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="text-align: center; vertical-align: bottom"><td colspan="2" style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td><td style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td> <td colspan="3" style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none">Accumulated</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none">September 30, 2017</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none">December 31, 2016</td></tr> <tr style="text-align: center; vertical-align: bottom"> <td colspan="2" style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Cost</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Depletion</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Net Book Value</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; border-bottom: Black 1pt solid">Net Book Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Computer</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 16%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">6,482</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 16%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">5,971</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 15%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">511</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="width: 3%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="width: 15%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="width: 1%; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Software</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">5,000</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">5,000</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none; text-align: right"> </td><td style="font: normal 10pt Calibri, Helvetica, Sans-Serif; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">11,482</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">10,971</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">511</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Greenhouse</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">330,026</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">9,167</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">320,859</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left; vertical-align: bottom">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">341,508</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">20,138</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">321,370</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td><td style="font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"> <tr style="vertical-align: bottom"> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td colspan="3" style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center">September 30, 2017</td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center">December 31, 2016</td></tr> <tr style="vertical-align: bottom"> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Cost</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Accumulated Depletion</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: normal; font-style: normal; text-transform: none; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: normal; text-transform: none; text-align: left">Property Farming Rights</td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">Fort McDermit Allottees Land</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">50,000</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">4,723</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">45,277</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="width: 10%; font-weight: normal; font-style: normal; text-transform: none; text-align: right">47,778</td> <td style="width: 1%; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left">Washoe Tribal Allotment Lands</td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">640,000</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">20,252</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">619,748</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right">638,948</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt">Winnemucca Tribal MBS Lands</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">200,000</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">4,904</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">195,096</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">0</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">890,000</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">29,879</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">860,121</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: normal; font-style: normal; text-transform: none; text-align: right">686,726</td> <td style="padding-bottom: 1pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt">Operating capital for Washoe Lands</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">85,000</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid"> </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">—  </td> <td style="font-family: Calibri, Helvetica, Sans-Serif; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">85,000</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 1pt"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: right; border-bottom: Black 1pt solid">—  </td> <td style="font-weight: normal; font-style: normal; text-transform: none; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt">Total</td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">975,000</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">29,879</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">945,121</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td> <td style="font-weight: normal; font-style: normal; text-transform: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-weight: normal; font-style: normal; text-transform: none; text-align: right">686,726</td> <td style="padding-bottom: 2.5pt; font-weight: normal; font-style: normal; text-transform: none; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, 2017</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Intellectual assets, primarily intellectual property</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">660,299</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">660,299</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,688</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(520,549</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(488,299</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Impairment of Goodwill</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(170,688</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(170,688</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">172,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">September 30, 2017</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">December 31, 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Prepaid consulting expenses</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">130,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">141,750</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Prepaid Legal fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Prepaid rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Prepaid management fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Deposits held with RMS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">42,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">576,520</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deposit for acquisition of Jinvator</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">65,214</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total Prepaid expenses and Deposits held with RMS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268,448</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">808,514</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

0.064

0.05

0.04

0.075

0.02

0.015

0.02

0.03

0.025

10000000

0.010

0.041

1700000

15000000 0.075

P2Y

0.0250

137.2697

0.00

0.90

0.301

0.749

0.501

1200000

60000

10000000

0.10

On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with Jinvator BioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. On March 27, 2017, the Company entered an agreement to acquire the Assets of AFA Research and Development, a California sole proprietorship of Aja Fonseca Arnold in the research and development of products based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.

60000

65214

A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.

The advances with no interest and no security.

The debt with no interest and no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.

The debt with no interest and no security and is due on demand. The loan originated on August 14, 2015 for expenses of the Company.

The debt with no interest and no security and is due on demand. The loan originated from January 11, 2016 to September 30, 2017 for expenses of the Company.

The debt with no interest and no security and is due on demand. The loan originated from April 22, 2011 to December 31, 2014.

The Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.

As of March 31, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.

The notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 2016. All promissory notes are unsecured.

The notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 2016. All promissory notes are unsecured.

7500000

5000000

2500000

150000

262250

187500

0.0155 0.03 0.1049 0.025

0.0289

0.1078

The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the dupetit Natural Products GmbH joint-venture operating agreement to Omnicanna under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Omnicanna under an Asset Purchase Agreement.

797518

860790

272518

710790

150000

375000

144000

Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters.

These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State.

1340156

1467925 1531197

250000000

250000

975407 710790 150000 375000

0.001

The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and amortize it over the life of the Note.

0.001

These shares have full voting rights.

These shares have 10 votes per share.

121500000

-15000000

350000

700000

271500

1270500

883000

1324500

469000

93600

1062500

1392000

The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement:   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">(i)</td><td>the option to purchase 100,000 common shares at ten cents ($0.10) per share;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">(ii)</td><td>the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">(iii)</td><td>the option to purchase 100,000 common shares at twenty cents ($0.20) per share;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.5in">(iv)</td><td>the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.</td></tr></table>

1,700,000 shares of these options at an average exercise price of $0.41 a share, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane. On March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two initial payments of $50,000 for licensing and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA.  Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products.  All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses. On October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is 40% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. On November 12, 2016, the Company entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. On December 18, 2016, the Company enter six (9) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. On December 21, 2016, the Company enter two (2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. On May 18, 2017, the Company entered an Exclusive Master Facilitator Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit Organics, LLC (FSO), American Education Consulting Group, Raymond C. Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to lease and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and retain 5% of net profit as master facilitator.

The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.

The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

212000

P2Y

P5Y

P3Y

This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.

85277

247500

-71250

144000

Straight-line method

P5Y

The Company

San Joaquin County and DEA

Iillegal seizure of cultivated industrial hemp crops from HRM Farm in Winnemucca Tribal Land for return of the seized properties.

October 27, 2017

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year. 3521000 110650 7226505 -3816075 3521080

375000

1847438

1674

0.00

-0.01

0.00

107750

371695

-10850000

-3500000

-7350000

686726

45277

619748

85000

860121

686726

47778

638948

195096

945121

EX-101.SCH 7 cbis-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements Of Operations And Other Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements Of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements Of Stockholders' (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary Of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Fair Value Measurements And Disclosures link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equipment And Greenhouse link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Property Farming Rights link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Equity Method Investee link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Goodwill And Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Prepaid Expenses And Deposits Held With RMS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary Of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Property Farming Rights (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Goodwill And Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Prepaid Expenses And Deposits Held With RMS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equity Transactions (Schedule Of Stock Options Outstanding) (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Equity Transactions (Schedule Of Weighted Average Fair Value Assumptions Of Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Equipment And Greenhouse (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Property Farming Rights (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Goodwill And Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Prepaid Expenses And Deposits Held With RMS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Related Party Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Related Party Transactions (Narrative) (Details1) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Notes Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equity Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Equity Transactions (Narrative) (Details1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Property Farming Rights (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Equity Method Investee (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Goodwill And Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Subsequent Events (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cbis-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cbis-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cbis-20170930_lab.xml XBRL LABEL FILE Award Type [Axis] Stock Option [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual property And Goodwill [Member] Related Party [Axis] Alfredo Bernardi Dupetit - President & CEO Of Cannabis Science Europe GmbH [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Common Class A [Member] Property, Plant and Equipment, Type [Axis] Software [Member] Computers [Member] Property Farming Rights - Fort McDermit Allottees Land [Member] Property Farming Rights - Washoe Tribal Allotment Lands [Member] Agreement [Axis] Management And Paying Agent Agreement With Royalty Management Services Corp (RMS) [Member] Equity Components [Axis] Common Shares [Member] Preferred Shares [Member] Additional Paid-In Capital [Member] Prepaid Consulting [Member] Accumulated Deficit [Member] Common Stock Receivable [Member] Cumulative Exchange Translation [Member] Equity Attributable to Common Shareholders [Member] Non-Controlling Interest [Member] Greenhouse [Member] Sub Total Of Computer And Software [Member] Property Farming Rights - Operating Capital For Washoe Lands [Member] Sub Total Of Allotment For Lands [Member] Dr. Allen Herman - Chief Medical Officer [Member] Property Farming Rights - Winnemucca Tribal MBS Lands [Member] Consolidated Entities [Axis] Cannabis Science Europe GmbH [Member] Business Acquisition [Axis] Michigan Green Technologies, LLC [Member] Noncash or Part Noncash Acquisitions by Unique Description [Axis] Asset Acquisition of Equi-Pharm LLC [Member] Share Purchase Agreement With Jinvator BioMed GmbH [Member] Currency [Axis] Euros Asset Purchase Agreement [Member] Raymond Dabney - CEO [Member] Mario Lap - Director [Member] Robert Kane - Director, COO [Member] Robert Kane, CFO Through His Company, R Kane Holding Inc., [Member] Short-term Debt, Type [Axis] Loans Payable [Member] Crown Baus Capital Corp - A Company Controlled By Raymond C. Dabney, CEO [Member] Interstate 101 - Shareholder [Member] Castor Management Services - Shareholder [Member] Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] MJR BV - Owned By Mario Lap, Director [Member] Robert Melamede - Former CEO [Member] Drue Young - Shareholder [Member] Intrinsic Venture Corp. - Shareholder [Member] OmniCanna Health Solutions, Inc. Related With Management - Director, CEO, CFO, COO [Member] Investment, Name [Axis] Equity Method Investment In OmniCanna Health Solutions, Inc. [Member] Royalty Management Services Corp., - Company Owned By Family Member Of Mr. Raymond C. Dabney, CEO [Member] Convertible Notes Payable [Member] Constituency For Africa, Charitable Organization - Raymond C. Dabney, Board Member [Member] Embella Holdings Ltd [Member] Notes Payable [Member] Intrinsic Capital Corp [Member] Note Payable To Stockholder [Member] Two-Year Convertible Promissory Note Dated August 10, 2016 [Member] Rule 144 Restricted Stock [Member] One-Year Convertible Promissory Note Dated October 01, 2016 [Member] One-Year Convertible Promissory Note Dated December 31, 2016 [Member] One-Year Convertible Promissory Note Dated May 31, 2017 [Member] Consulting Agreement [Member] Consulting Agreement Dated January 13, 2017 [Member] Supplier [Axis] Consultant [Member] Two Year Consulting Agreement [Member] Consulting Agreement Dated March 7, 2017 [Member] Plan Name [Axis] 2016 Equity Award Plan B [Member] Consulting Agreement Dated July 06, 2016 [Member] Consulting Agreement Dated April 29, 2015 [Member] One Year Consulting Agreement [Member] Three Month Marketing Agreement [Member] Two Year Consulting Agreement Dated August 10, 2017 [Member] Two Consultants [Member] Title of Individual [Axis] V.P Of Investor Relations, CFO And Director For Services [Member] Option Agreement [Member] Alfredo Dupetit-Bernardi - President/CEO of Cannabis Science Europe GmbH [Member] Five Year Consulting Agreement [Member] Dr. Allen Herman - Cheif Medical Officer [Member] 2016 Equity Award Plan B [Member] Joint Venture License Agreement With Ft. McDermitt Allotment Land Allotees [Member] Master Facilitator Agreement With Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member] Exclusive Master Facilitator Agreement With Members of Washoe Tribal Allotments, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member] Six Exclusive Master Facilitator Agreement With Members of Washoe Tribal Allotments, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member] Two Exclusive Master Facilitator Agreement With Members of Washoe Tribal Allotments, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member] Exclusive Master Facilitator Agreement With Winnemucca Tribal MBS Of Neveda, Free Spirit Organics, LLC, American Education Consulting Group, Raymond C. Dabney University, American States University And Royalty Management Services Corp (RMS) [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Computer [Member] Equipment And Laboratory Equipment [Member] Automobile [Member] Intellectual Assets [Member] Goodwill [Member] Litigation Case [Axis] Suit Against San Joaquin County and DEA For Illegal Seizure [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Other receivables Prepaid expenses and deposits held with RMS (Note 11) Inventory Total current assets Equipment and Greenhouse, net (Note 7) Property Farming Rights (Note 8) Equity method investee (Note 9) Intangibles, net of accumulated amortization (Note 10) TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable Accrued expenses, primarily management fees (Note 4) Advances from related parties (Note 4) Management bonuses Notes payable to stockholders (Note 5) Notes payable to related party (Note 5) Total current liabilities and total liabilities Stockholders' Deficit Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at September 30, 2017 and December 31, 2016 Common stock, $.001 par value, 3,000,000,000 shares authorized, 2,521,005,296 issued and outstanding as of September 30, 2017 and 2,350,355,296 at December 31, 2016; Common stock, Class A, $.001 par value, 100,000,000 shares authorized, 0 issued and outstanding as of September 30, 2017 and December 31, 2016 Additional paid-in capital Prepaid consulting Common Stock receivable Accumulated deficit Cumulative exchange translation Equity attributable to common shareholders Non-Controlling interest Total stockholders' deficit TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT Preferred stock, par value per share Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUE Cost of Goods Sold Gross Profit Operating Expenses Investor relations Professional Fees Net loss on settlement of liabilites Loss on investment Depreciation and Amortization Research and Development General and administrative Total operating expenses Net Operating Loss Other income (expense) Interest expense, net Unrealized loss on equity investee Total other income (expense) Net Loss Net (Income) loss attributable to non-controlling interest Net loss attributable to common shareholders Other Comprehensive Income (Loss) Foreign exchange translation adjustment Total other comprehensive income (Loss) Comprehensive loss attributable to Cannabis Science, Inc. Net loss per common share: Basic and diluted EX-101.PRE 11 cbis-20170930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Oct. 16, 2017
Document And Entity Information
Entity Registrant Name	CANNABIS SCIENCE, INC.
Entity Central Index Key	0001024626
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	2,521,095,296	2,551,805,296
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash	$ 29,294	$ 332,888
Other receivables	22,715	36,001
Prepaid expenses and deposits held with RMS (Note 11)	268,448	808,514
Inventory	151,675	102,993
Total current assets	472,132	1,280,396
Equipment and Greenhouse, net (Note 7)	321,370	0
Property Farming Rights (Note 8)	945,121	751,726
Equity method investee (Note 9)	202,477	272,644
Intangibles, net of accumulated amortization (Note 10)	139,750	172,000
TOTAL ASSETS	2,080,850	2,476,766
Current Liabilities
Accounts payable	773,950	856,269
Accrued expenses, primarily management fees (Note 4)	1,267,745	884,465
Advances from related parties (Note 4)	627,066	538,425
Management bonuses	300,000	300,000
Notes payable to stockholders (Note 5)	1,758,655	1,506,745
Notes payable to related party (Note 5)	510,018	177,698
Total current liabilities and total liabilities	5,237,434	4,263,602
Stockholders' Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at September 30, 2017 and December 31, 2016	1,000	1,000
Common stock, $.001 par value, 3,000,000,000 shares authorized, 2,521,005,296 issued and outstanding as of September 30, 2017 and 2,350,355,296 at December 31, 2016; Common stock, Class A, $.001 par value, 100,000,000 shares authorized, 0 issued and outstanding as of September 30, 2017 and December 31, 2016	2,521,006	2,350,356
Additional paid-in capital	148,164,025	136,963,520
Prepaid consulting	3,674,296	1,705,659
Common Stock receivable	1,275,774	655,000
Accumulated deficit	(148,335,348)	(138,137,771)
Cumulative exchange translation	(9,821)	(11,495)
Equity attributable to common shareholders	(2,609,208)	(1,195,049)
Non-Controlling interest	(547,376)	(591,787)
Total stockholders' deficit	(3,156,584)	(1,786,836)
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT	2,080,850	2,476,766
Series A Preferred Stock [Member]
Stockholders' Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at September 30, 2017 and December 31, 2016	1,000	1,000
Equity attributable to common shareholders	1,000	1,000
Total stockholders' deficit	1,000	1,000
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT	1,000	1,000
Common Class A [Member]
Stockholders' Deficit
Common stock, $.001 par value, 3,000,000,000 shares authorized, 2,521,005,296 issued and outstanding as of September 30, 2017 and 2,350,355,296 at December 31, 2016; Common stock, Class A, $.001 par value, 100,000,000 shares authorized, 0 issued and outstanding as of September 30, 2017 and December 31, 2016
Equity attributable to common shareholders
Total stockholders' deficit
TOTAL LIABILTIES AND STOCKHOLDERS' DEFICIT

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	2,521,005,296	2,350,355,296
Common stock, shares outstanding	2,521,005,296	2,350,355,296
Series A Preferred Stock [Member]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common Class A [Member]
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements Of Operations And Other Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
REVENUE	$ 2,317	$ 2,733	$ 6,302	$ 8,520
Cost of Goods Sold	1,183	1,407	3,245	3,609
Gross Profit	1,134	1,326	3,057	4,911
Operating Expenses
Investor relations	170,339	48,950	310,450	267,300
Professional Fees	68,501	58,962	343,590	254,079
Net loss on settlement of liabilites		(3,550,000)		(4,138,645)
Loss on investment		(971,500)		(971,500)
Depreciation and Amortization	16,345	19,284	41,672	57,853
Research and Development	125,513	6,487	511,345	265,024
General and administrative	2,720,660	2,301,712	7,855,375	6,082,880
Total operating expenses	3,101,358	6,956,895	9,062,432	12,037,281
Net Operating Loss	(3,100,224)	(6,955,569)	(9,059,375)	(12,032,370)
Other income (expense)
Interest expense, net	392,956		1,022,541	902
Unrealized loss on equity investee	(19,500)		(71,250)
Total other income (expense)	(412,456)		(1,093,791)	(902)
Net Loss	(3,512,680)	(6,955,569)	(10,153,166)	(12,033,272)
Net (Income) loss attributable to non-controlling interest	(1,344)		44,411	(78,413)
Net loss attributable to common shareholders	(3,511,336)	(6,955,569)	(10,197,577)	(11,954,859)
Other Comprehensive Income (Loss)
Foreign exchange translation adjustment	3,037	(201)	1,674	392
Total other comprehensive income (Loss)	3,037	(201)	1,674	392
Comprehensive loss attributable to Cannabis Science, Inc.	$ (3,508,299)	$ (6,955,770)	$ (10,195,903)	$ (11,954,467)
Net loss per common share:
Basic and diluted	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
Weighted average number of common shares outstanding	2,468,885,731	2,106,170,513	2,426,212,256	1,894,510,405

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements Of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,153,166)	$ (12,033,272)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	169,527	57,853
Charitable donation	40,000
Interest on debt conversion	1,022,502
Stock issued for services	5,368,518	3,825,874
Stock options issued for services	1,909,000	1,138,500
Loss on investment		(971,500)
Loss on settlement of liability		(4,138,645)
Loss on Equity Investee	(71,250)
Changes in operating assets and liabilities:
Other receivables	(13,286)	(4,173)
Prepaid expenses and deposits held with RMS	(438,816)	(11,250)
Equity investee	1,083	321
Inventory	48,682	73,739
Property farming rights	220,000
Accounts payable	292,681	411,616
Accrued expenses, primarily management fees	383,280	812,218
Loan receivable, related parties	(88,641)
NET CASH USED IN OPERATING ACTIVITES	(625,430)	(735,703)
CASH FLOWS FROM INVESTING ACTIVITIES
Advances receivable, related parties		17,516
Prepaid Expenses		244
Equipment and computers	766
Greenhouse	330,026
Property farming rights		48,611
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES	(330,792)	(31,339)
CASH FLOWS FROM FINANCING ACTIVITIES
Loan receivable, related parties		82,369
Proceeds from notes payable to stockholders		295,855
Repayment of notes payable to stockholders	438,272	295,000
Proceeds from common stock options exercised	1,089,226	632,500
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	650,954	715,724
Effect on exchange rate changes on cash	1,674	392
NET DECREASE IN CASH	(303,594)	(50,926)
CASH, BEGINNING OF PERIOD	332,888	61,971
CASH, END OF PERIOD	29,294	11,045
SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for services	5,368,518	1,816,732
Common stock issued for settlement of debt		$ 4,434,500
Common stock issued for options exercised	1,909,000	3,888,500
Common stock issued for assets		$ 271,350
Debt converted into common stock		295,000
Common stock subscription receivables	1,275,774	2,499
Related Party Receivable - RCDU		20,000
Accounts payable and expenses paid through advances from related parties	$ 88,641	$ 29,852

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements Of Stockholders' (Deficit) - 9 months ended Sep. 30, 2017 - USD ($)	Common Shares [Member]	Preferred Shares [Member]	Additional Paid-In Capital [Member]	Prepaid Consulting [Member]	Common Stock Receivable [Member]	Accumulated Deficit [Member]	Cumulative Exchange Translation [Member]	Equity Attributable to Common Shareholders [Member]	Non-Controlling Interest [Member]	Total
Balance Common stock, shares at Dec. 31, 2016	2,350,355,296									2,350,355,296
Balance Preferred stock, shares at Dec. 31, 2016		1,000,000								1,000,000
Balance, value at Dec. 31, 2016	$ 2,350,356	$ 1,000	$ 136,963,520	$ (1,705,659)	$ (655,000)	$ (138,137,771)	$ (11,495)	$ (1,195,049)	$ (591,787)	$ (1,786,836)
Common stock issued for services, shares	110,650,000
Common stock issued for services, value	$ 110,650		7,226,505	(3,816,075)				3,521,080		$ 3,521,000
Common stock issued for stock option exercised, shares	60,000,000									75,000,000
Common stock issued for stock option exercised, value	$ 60,000		3,599,000		(620,774)			3,038,226		$ 3,038,226
Intrinsic interest on convertible promissory notes			375,000					375,000		375,000
Amortization of shares issued for services				1,847,438				1,847,438		1,847,438
Net loss for the period						(10,197,577)		(10,197,577)	44,411	(10,153,166)
Foreign exchange translation							1,674	1,674		$ 1,674
Balance Common stock, shares at Sep. 30, 2017	2,521,005,296									2,521,005,296
Balance Preferred stock, shares at Sep. 30, 2017		1,000,000								1,000,000
Balance, value at Sep. 30, 2017	$ 2,521,006	$ 1,000	$ 148,164,025	$ (3,674,296)	$ (1,275,774)	$ (148,335,348)	$ (9,821)	$ (2,609,208)	$ (547,376)	$ (3,156,584)

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Organization and General Description of Business

On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC Pink: CBIS.

B. Basis of Presentation

Interim Financial Reporting

The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the nine months ended September 30, 2017:

For other accounting policies please refer to the Company’s 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Sep. 30, 2017

Going Concern

Going Concern

2. GOING CONCERN

XML 20 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements And Disclosures

9 Months Ended

Sep. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements and Disclosures

3. FAIR VALUE MEASUREMENTS AND DISCLOSURES

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2017

Related Party Transactions

4. RELATED PARTY TRANSACTIONS

At September 30, 2017, a total of $229,180 (December 31, 2016: $14,200) in Accrued Management Fees Payable was due to the Company’s CEO/Director, Raymond C. Dabney.

At September 30, 2017, a total Prepaid management fees of $30,000 (December 31, 2016: Prepaid $52,500) advanced to the Company’s Director, Mario Lap.

At September 30, 2017, a total of $105,000 (December 31, 2016: Prepaid $30,000) in Accrued Management Fees Payable was due to the Company’s COO/Director, Robert Kane.

At September 30, 2017, a total of $191,344 (December 31, 2016: $191,344) in loans payable was due to Bogat Family Trust, of which Raymond Dabney the Company’s Director and President/CEO as trustee.

At September 30, 2017, $106,186 (December 31, 2016: $93,885) was due to MJR BV, owned by Mario Lap director and director and officer of EU subsidiaries.

At September 30, 2017, $447 (December 31, 2016: $447) was due to Robert Melamede, former CEO.

On July 2, 2017, the Company donated $40,000 to Constituency For Africa, a charitable organization found in United States for the people in Africa, of which Mr. Raymond C. Dabney is a Board member.

On November 5, 2014, the Company transitioned to equity method investee accounting for the OmniCanna shares pursuant to ASC 323 recording $247,500 as the fair value of the shares to its equity method investee account. On December 31, 2016, the Company recorded an impairment on the equity method investee account of $144,000 in relation to the shares. Robert Kane, COO and director of the Company is also the COO and a director of OmniCanna. Benjamin Tam, CFO and a director is also a director and CFO of Omnicanna. Raymond Dabney, CEO has 10.78% equity interest in Omniccanna Health Solutions, Inc. as of September 30, 2017.

For the nine months ended September 30, 2017, the following related party stock-based compensation was recorded:

Related Party	Position	Amount
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH	$	415,000
Dr. Allen Herman	Chief Medical Officer		595,000
		$	1,010,000

¹Including compensation to entities beneficially owned/control by the related parties

See Note 6 -Equity Transactions for details of stock issuances to director and officers for services rendered.

Notes payable to Intrinsic Capital Corp. totaled $231,260 and $231,260 at September 30, 2017 and December 31, 2016, respectively. See Note 5.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Notes Payable

5. NOTES PAYABLE

XML 23 R12.htm IDEA: XBRL DOCUMENT

Equity Transactions

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Equity Transactions

6. EQUITY TRANSACTIONS

As set out below, we have issued securities in exchange for services, properties and for debt, using exemptions available under the Securities Act of 1933.

Stock Options:

The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement:

(i)

the option to purchase 100,000 common shares at ten cents ($0.10) per share;

(ii)

the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and

(iii)

the option to purchase 100,000 common shares at twenty cents ($0.20) per share;

(iv)

the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.

On August 10, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.03 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement.

A summary of the status of the Company’s option grants as of September 30, 2017 and the changes during the period then ended is presented below:

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2016		11,700,000	$	0.069
Granted		75,000,000	$	0.064
Exercised		75,000,000	$	0.064
Expired		10,000,000	$	0.010
Outstanding September 30, 2017		1,700,000	$	0.041

Options exercisable at September 30, 2017		1,700,000	$	0.041
Shares issued under option agreement to be returned and cancelled		15,000,000	$	0.075

Average expected life in years for outstanding options	2	Years
Average risk-free interest rate	2.50	%
Average volatility	137.2697	%
Dividend yield	0	%

XML 24 R13.htm IDEA: XBRL DOCUMENT

Equipment And Greenhouse

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Equipment and Greenhouse

7. EQUIPMENT AND GREENHOUSE

			Accumulated		September 30, 2017		December 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Computer	$	6,482	$	5,971	$	511	$	0
Software		5,000		5,000		0		0
		11,482		10,971		511		0
Greenhouse	$	330,026	$	9,167	$	320,859	$	0
Total	$	341,508	$	20,138	$	321,370	$	0

XML 25 R14.htm IDEA: XBRL DOCUMENT

Property Farming Rights

9 Months Ended

Sep. 30, 2017

Property Farming Rights

Property Farming Rights

8. PROPERTY FARMING RIGHTS

					September 30, 2017		December 31, 2016
	Cost		Accumulated Depletion		Net Book Value		Net Book Value
Property Farming Rights
Fort McDermit Allottees Land	$	50,000	$	4,723	$	45,277	$	47,778
Washoe Tribal Allotment Lands		640,000		20,252		619,748		638,948
Winnemucca Tribal MBS Lands		200,000		4,904		195,096		0
		890,000	$	29,879		860,121		686,726
Operating capital for Washoe Lands	$	85,000		—	$	85,000	$	—
Total	$	975,000	$	29,879	$	945,121	$	686,726

All property farm rights are amortized over the term of each respective agreements.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Equity Method Investee

9 Months Ended

Sep. 30, 2017

Equity Method Investee

Equity Method Investee

9. EQUITY METHOD INVESTEE

XML 27 R16.htm IDEA: XBRL DOCUMENT

Goodwill And Intangible Assets

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Goodwill and Intangible Assets

10. GOODWILL and INTANGIBLE ASSETS

	September 30, 2017			December 31, 2016
Intellectual assets, primarily intellectual property	$	660,299		$	660,299
Goodwill		170,688			170,688
Less: accumulated amortization		(520,549	)		(488,299	)
Less: Impairment of Goodwill		(170,688	)		(170,688	)
Total intangible assets, net	$	139,750		$	172,000

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Prepaid Expenses And Deposits Held With RMS

9 Months Ended

Sep. 30, 2017

Prepaid Expenses And Deposits Held With Rms

Prepaid Expenses and Deposits Held with RMS

11. PREPAID EXPENSES AND DEPOSITS HELD WITH RMS

	September 30, 2017		December 31, 2016
Prepaid consulting expenses	$	130,500	$	141,750
Prepaid Legal fees		—		90,000
Prepaid rent		244		244
Prepaid management fees		30,000		—
Deposits held with RMS		42,490		576,520
Deposit for acquisition of Jinvator		65,214		—
Total Prepaid expenses and Deposits held with RMS	$	268,448	$	808,514

XML 29 R18.htm IDEA: XBRL DOCUMENT

Commitments

9 Months Ended

Sep. 30, 2017

Commitments

Commitments

12. COMMITMENTS

XML 30 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

13. SUBSEQUENT EVENTS

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies (Policies)	9 Months Ended
Summary Of Significant Accounting Policies (Policies)	Sep. 30, 2017
Summary Of Significant Accounting Policies Policies
Organization and General Description of Business	A. Organization and General Description of Business Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC Pink: CBIS. Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 ^th and May 6 ^th, 2013, respectively, to pursue business opportunities in Europe and worldwide. There are currently minimal operations in the subsidiaries. Agreements and business disclosures are in process. On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neuro behavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neuro behavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.
Basis of Presentation	B. Basis of Presentation These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year end is December 31. Interim Financial Reporting While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2016 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine-month periods ended September 30, 2017 and 2016. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2016 included in our Form 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017. Operating results for the nine months ended September 30, 2017 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017. The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the nine months ended September 30, 2017: In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) in which the Company own 90% to operate joint-venture operations with Dupetit Natural Products Ltd. The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012. No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany. On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV, MJR BV and Cannabis Agency BV, all are Netherlands registered companies. On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT. On May 6, 2015, the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. in the state of Tennessee and started the operation of distributing of existing and new line of products. On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with JinvatorBioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. Jinvator developed a prototype called nanoGold-Test which is based on nano-particle technology for the detection of HIV in the early stage of infection. Patent has been submitted and pending for approval.The acquisition is pending on verification of key information. On May 10, 2017, the Company paid €60,000, which has a US dollar equivalent of $65,214, to the principal shareholder of JinvatorBioMed GmbH (Jinvator) as deposit for the purchase of the 74.9% equity interest in Jinvator. On March 27, 2017, the Company entered an agreement to acquire the Assets of AFA Research and Development, a California sole proprietorship of Aja Fonseca Arnold in the research and development of products based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments. For other accounting policies please refer to the Company’s 10-K/A filed with the SEC on file no. 000-28911 171022778 August 11, 2017. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2017

Related Party Transactions Tables

Schedule of Stock Based Compensation with Related Party

For the nine months ended September 30, 2017, the following related party stock-based compensation was recorded:

Related Party	Position	Amount
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH	$	415,000
Dr. Allen Herman	Chief Medical Officer		595,000
		$	1,010,000

¹Including compensation to entities beneficially owned/control by the related parties

XML 33 R22.htm IDEA: XBRL DOCUMENT

Equity Transactions (Tables)

9 Months Ended

Sep. 30, 2017

Equity Transactions Tables

Schedule of Stock Options Outstanding

A summary of the status of the Company’s option grants as of September 30, 2017 and the changes during the period then ended is presented below:

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2016		11,700,000	$	0.069
Granted		75,000,000	$	0.064
Exercised		75,000,000	$	0.064
Expired		10,000,000	$	0.010
Outstanding September 30, 2017		1,700,000	$	0.041

Options exercisable at September 30, 2017		1,700,000	$	0.041
Shares issued under option agreement to be returned and cancelled		15,000,000	$	0.075

Schedule of Weighted Average Fair Value Assumptions of Stock Option

The weighted average fair value at date of grant for options during year ended September 30, 2017 was estimated using the Black-Scholes option valuation model with the following:

Average expected life in years for outstanding options	2	Years
Average risk-free interest rate	2.50	%
Average volatility	137.2697	%
Dividend yield	0	%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Equipment (Tables)

9 Months Ended

Sep. 30, 2017

Equipment Tables

Schedule of Property Plant and Equipment Assets

			Accumulated		September 30, 2017		December 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Computer	$	6,482	$	5,971	$	511	$	0
Software		5,000		5,000		0		0
		11,482		10,971		511		0
Greenhouse	$	330,026	$	9,167	$	320,859	$	0
Total	$	341,508	$	20,138	$	321,370	$	0

XML 35 R24.htm IDEA: XBRL DOCUMENT

Property Farming Rights (Tables)

9 Months Ended

Sep. 30, 2017

Property Farming Rights Tables

Schedule of Property Farming Rights

					September 30, 2017		December 31, 2016
	Cost		Accumulated Depletion		Net Book Value		Net Book Value
Property Farming Rights
Fort McDermit Allottees Land	$	50,000	$	4,723	$	45,277	$	47,778
Washoe Tribal Allotment Lands		640,000		20,252		619,748		638,948
Winnemucca Tribal MBS Lands		200,000		4,904		195,096		0
		890,000	$	29,879		860,121		686,726
Operating capital for Washoe Lands	$	85,000		—	$	85,000	$	—
Total	$	975,000	$	29,879	$	945,121	$	686,726

XML 36 R25.htm IDEA: XBRL DOCUMENT

Goodwill And Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill And Intangible Assets Tables

Schedule of Goodwill and Intangible Assets

	September 30, 2017			December 31, 2016
Intellectual assets, primarily intellectual property	$	660,299		$	660,299
Goodwill		170,688			170,688
Less: accumulated amortization		(520,549	)		(488,299	)
Less: Impairment of Goodwill		(170,688	)		(170,688	)
Total intangible assets, net	$	139,750		$	172,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Prepaid Expenses And Deposits Held With RMS (Tables)

9 Months Ended

Sep. 30, 2017

Prepaid Expenses And Deposits Held With Rms Tables

Schedule of Prepaid Expenses and Deposits Held with RMS

	September 30, 2017		December 31, 2016
Prepaid consulting expenses	$	130,500	$	141,750
Prepaid Legal fees		—		90,000
Prepaid rent		244		244
Prepaid management fees		30,000		—
Deposits held with RMS		42,490		576,520
Deposit for acquisition of Jinvator		65,214		—
Total Prepaid expenses and Deposits held with RMS	$	268,448	$	808,514

XML 38 R27.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details)	9 Months Ended
Related Party Transactions (Details)	Sep. 30, 2017 USD ($)
Related Party Transaction [Line Items]
Stock based compensation	$ 1,010,000
Alfredo Bernardi Dupetit - President & CEO Of Cannabis Science Europe GmbH [Member]
Related Party Transaction [Line Items]
Stock based compensation	415,000
Dr. Allen Herman - Chief Medical Officer [Member]
Related Party Transaction [Line Items]
Stock based compensation	$ 595,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Equity Transactions (Schedule Of Stock Options Outstanding) (Details)	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Shares
Outstanding December 31, 2016 \| shares	11,700,000
Granted \| shares	75,000,000
Exercised \| shares	75,000,000
Expired \| shares	10,000,000
Outstanding September 30, 2017 \| shares	1,700,000
Options exercisable at September 30, 2017 \| shares	1,700,000
Shares issued under option agreement to be returned and cancelled \| shares	15,000,000
Weighted-Average Exercise Price
Outstanding December 31, 2016 \| $ / shares	$ 0.069
Granted \| $ / shares	0.064
Exercised \| $ / shares	0.064
Expired \| $ / shares	0.010
Outstanding September 30, 2017 \| $ / shares	0.041
Options exercisable at September 30, 2017 \| $ / shares	0.041
Shares issued under option agreement to be returned and cancelled \| $ / shares	$ 0.075

XML 40 R29.htm IDEA: XBRL DOCUMENT

Equity Transactions (Schedule Of Weighted Average Fair Value Assumptions Of Stock Options) (Details) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2017
Fair value of Stock Options - Black Scholes Options Valuation Model
Average expected life in years for outstanding options	2 years
Average risk-free interest rate	2.50%
Average volatility	13726.97%
Dividend yield	0.00%

XML 41 R30.htm IDEA: XBRL DOCUMENT

Equipment And Greenhouse (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Equipment Cost , Gross	$ 341,508	$ 0
Accumulated Depreciation	20,138	0
Equipment Cost, Net	321,370	$ 0
Computers [Member]
Property, Plant and Equipment [Line Items]
Equipment Cost , Gross	6,482
Accumulated Depreciation	5,971
Equipment Cost, Net	511
Software [Member]
Property, Plant and Equipment [Line Items]
Equipment Cost , Gross	5,000
Accumulated Depreciation	5,000
Equipment Cost, Net	0
Sub Total Of Computer And Software [Member]
Property, Plant and Equipment [Line Items]
Equipment Cost , Gross	11,482
Accumulated Depreciation	10,971
Equipment Cost, Net	511
Greenhouse [Member]
Property, Plant and Equipment [Line Items]
Equipment Cost , Gross	330,026
Accumulated Depreciation	9,167
Equipment Cost, Net	$ 320,859

XML 42 R31.htm IDEA: XBRL DOCUMENT

Property Farming Rights (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property Farming Rights
Cost	$ 975,000
Accumulated Depletion	29,879
Net Book Value	945,121	$ 686,726
Property Farming Rights - Fort McDermit Allottees Land [Member]
Property Farming Rights
Cost	50,000
Accumulated Depletion	4,723
Net Book Value	45,277	47,778
Property Farming Rights - Washoe Tribal Allotment Lands [Member]
Property Farming Rights
Cost	640,000
Accumulated Depletion	20,252
Net Book Value	619,748	638,948
Property Farming Rights - Winnemucca Tribal MBS Lands [Member]
Property Farming Rights
Cost	200,000
Accumulated Depletion	4,904
Net Book Value	195,096	0
Sub Total Of Allotment For Lands [Member]
Property Farming Rights
Cost	890,000
Accumulated Depletion	29,879
Net Book Value	860,121	686,726
Property Farming Rights - Operating Capital For Washoe Lands [Member]
Property Farming Rights
Cost	85,000
Accumulated Depletion
Net Book Value	$ 85,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Goodwill And Intangible Assets (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Less: accumulated amortization	$ 29,879
Total intangible assets, net	139,750	$ 172,000
Intellectual property And Goodwill [Member]
Intellecutal assets, primarily intellectual property	660,299	660,299
Goodwill	170,688	170,688
Less: accumulated amortization	520,549	488,299
Less: Impairment of Goodwill	170,688	170,688
Total intangible assets, net	$ 139,750	$ 172,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Prepaid Expenses And Deposits Held With RMS (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Total Prepaid expenses and Deposits held with RMS	$ 268,448	$ 808,514
Management And Paying Agent Agreement With Royalty Management Services Corp (RMS) [Member]
Prepaid consulting expenses	130,500	141,750
Prepaid Legal fees		90,000
Prepaid rent	244	244
Prepaid management fees	30,000
Deposits held with RMS	42,490	576,520
Deposit for acquisition of Jinvator	65,214
Total Prepaid expenses and Deposits held with RMS	$ 268,448	$ 808,514

XML 45 R34.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies (Narrative) (Details)							9 Months Ended
	May 10, 2017 USD ($)	May 10, 2017 EUR (€)	Mar. 27, 2017	Feb. 02, 2017	May 06, 2015 shares	Feb. 20, 2015 USD ($) shares	Sep. 30, 2017	Aug. 06, 2014	Dec. 31, 2012
Emerging growth company description							The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year.
Asset Purchase Agreement [Member]
Agreement terms			On March 27, 2017, the Company entered an agreement to acquire the Assets of AFA Research and Development, a California sole proprietorship of Aja Fonseca Arnold in the research and development of products based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.
Asset Acquisition of Equi-Pharm LLC [Member]
Stock issued for purchase of assets, shares \| shares					10,000,000
Michigan Green Technologies, LLC [Member]
Business acquisition of additional interest acquired percentage								30.10%
Business acquisition total ownership percentage						50.10%
Stock issued for acquisition, shares \| shares						1,200,000
Stock issued for acquisition, value \| $						$ 60,000
Cannabis Science Europe GmbH [Member]
Ownership interest by parent				90.00%					90.00%
Ownership interest by Dupetit Natural Products GmbH				10.00%
Cannabis Science Europe GmbH [Member] \| Share Purchase Agreement With Jinvator BioMed GmbH [Member]
Business acquisition of additional interest acquired percentage	74.90%	74.90%
Agreement terms				On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with Jinvator BioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430.
Payments made as deposit to acquire equity interest \| $	$ 65,214
Cannabis Science Europe GmbH [Member] \| Share Purchase Agreement With Jinvator BioMed GmbH [Member] \| Euros
Payments made as deposit to acquire equity interest \| €		€ 60,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Accrued management fees payable		$ 1,267,745		$ 884,465
Dues to related parties		627,066		538,425
Proceeds from related party			$ 82,369
Raymond Dabney - CEO [Member]
Related Party Transaction [Line Items]
Accrued management fees payable		229,180		14,200
Mario Lap - Director [Member]
Related Party Transaction [Line Items]
Accrued management fees payable		30,000		52,500
Robert Kane - Director, COO [Member]
Related Party Transaction [Line Items]
Accrued management fees payable		105,000		30,000
Robert Kane, CFO Through His Company, R Kane Holding Inc., [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties		$ 52,000		$ 52,500
Debt instrument description		A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.		A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.
Crown Baus Capital Corp - A Company Controlled By Raymond C. Dabney, CEO [Member]
Related Party Transaction [Line Items]
Dues to related parties		$ 11,871		$ 11,871
Debt instrument description		The advances with no interest and no security.		The advances with no interest and no security.
Proceeds from related party	$ 11,871
Interstate 101 - Shareholder [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties		$ 101,882		$ 101,882
Debt instrument description		The debt with no interest and no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.		The debt with no interest and no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.
Castor Management Services - Shareholder [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties		$ 3,165		$ 3,165
Debt instrument description		The debt with no interest and no security and is due on demand. The loan originated on August 14, 2015 for expenses of the Company.		The debt with no interest and no security and is due on demand. The loan originated on August 14, 2015 for expenses of the Company.
Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties		$ 191,344		$ 191,344
MJR BV - Owned By Mario Lap, Director [Member]
Related Party Transaction [Line Items]
Dues to related parties		106,186		93,885
Robert Melamede - Former CEO [Member]
Related Party Transaction [Line Items]
Dues to related parties		$ 447		$ 447

XML 47 R36.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Narrative) (Details1) - USD ($)			2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 02, 2017	Jul. 25, 2014	Mar. 07, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Nov. 05, 2014	Aug. 06, 2014	Feb. 08, 2013	Dec. 12, 2012
Related Party Transaction [Line Items]
Dues to related parties				$ 627,066		$ 627,066		$ 538,425
Unrealized gain (loss) on equity investee				(19,500)		(71,250)
Donated to charitable organization						40,000
Equity method investee				202,477		202,477		272,644
Due to officers or stockholders				1,758,655		$ 1,758,655		1,506,745
Proceeds from related party							$ 82,369
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock voting rights						These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State.
Michigan Green Technologies, LLC [Member]
Related Party Transaction [Line Items]
Business acquisition total ownership percentage										30.10%
Drue Young - Shareholder [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties				95,909		$ 95,909		$ 23,378
Debt instrument description						The debt with no interest and no security and is due on demand. The loan originated from January 11, 2016 to September 30, 2017 for expenses of the Company.		The debt with no interest and no security and is due on demand. The loan originated from January 11, 2016 to September 30, 2017 for expenses of the Company.
Intrinsic Venture Corp. - Shareholder [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties				$ 20,502		$ 20,502		$ 20,502
Debt instrument description						The debt with no interest and no security and is due on demand. The loan originated from April 22, 2011 to December 31, 2014.		The debt with no interest and no security and is due on demand. The loan originated from April 22, 2011 to December 31, 2014.
OmniCanna Health Solutions, Inc. Related With Management - Director, CEO, CFO, COO [Member] \| Equity Method Investment In OmniCanna Health Solutions, Inc. [Member]
Related Party Transaction [Line Items]
Common stock invested				7,500,000		7,500,000					2,500,000	5,000,000
Fair market value of common stock acquired under equity method investment								$ 187,500			$ 262,250	$ 150,000
Fair value of common stock acquired under equity method investment, per share				$ 0.0155		$ 0.0155		$ 0.025			$ 0.1049	$ 0.03
Equity method investment ownership percentage				2.89%		2.89%
Unrealized gain (loss) on equity investee						$ (116,250)
Equity method investee									$ 247,500
Impairment of equity method investment								$ 144,000
OmniCanna Health Solutions, Inc. Related With Management - Director, CEO, CFO, COO [Member] \| Equity Method Investment In OmniCanna Health Solutions, Inc. [Member] \| Asset Purchase Agreement [Member]
Related Party Transaction [Line Items]
Investment owned description						The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the dupetit Natural Products GmbH joint-venture operating agreement to Omnicanna under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Omnicanna under an Asset Purchase Agreement.
Royalty Management Services Corp., - Company Owned By Family Member Of Mr. Raymond C. Dabney, CEO [Member] \| Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Convertible notes payable				$ 797,518		$ 797,518		$ 860,790
Constituency For Africa, Charitable Organization - Raymond C. Dabney, Board Member [Member]
Related Party Transaction [Line Items]
Donated to charitable organization	$ 40,000
Raymond Dabney - CEO [Member] \| Equity Method Investment In OmniCanna Health Solutions, Inc. [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage				10.78%		10.78%
Embella Holdings Ltd [Member] \| Notes Payable [Member]
Related Party Transaction [Line Items]
Debt instrument description						The Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.		The Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.
Due to officers or stockholders				$ 1,108,896		$ 1,108,896		$ 1,108,896
Intrinsic Capital Corp [Member] \| Notes Payable [Member]
Related Party Transaction [Line Items]
Debt instrument description						As of March 31, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.		As of March 31, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date.
Due to officers or stockholders				231,260		$ 231,260		$ 231,260
Robert Kane, CFO Through His Company, R Kane Holding Inc., [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties				52,000		$ 52,000		$ 52,500
Debt instrument description						A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.		A non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.
Robert Kane, CFO Through His Company, R Kane Holding Inc., [Member] \| Loans Payable [Member] \| Michigan Green Technologies, LLC [Member]
Related Party Transaction [Line Items]
Proceeds from related party			$ 52,500
Business acquisition total ownership percentage			50.10%
Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] \| Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock voting rights		Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters.
Bogat Family Trust, Raymond Dabney - President/CEO As Trustee [Member] \| Loans Payable [Member]
Related Party Transaction [Line Items]
Dues to related parties				$ 191,344		$ 191,344		$ 191,344

XML 48 R37.htm IDEA: XBRL DOCUMENT

Notes Payable (Narrative) (Details) - USD ($)		3 Months Ended	5 Months Ended	9 Months Ended		12 Months Ended	14 Months Ended
Notes Payable (Narrative) (Details) - USD ($)	Aug. 10, 2016	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2017	May 31, 2017	Oct. 01, 2016
Short-term Debt [Line Items]
Notes payable to stockholders		$ 1,758,655	$ 1,506,745	$ 1,758,655		$ 1,506,745	$ 1,758,655
Repayments of notes payable				438,272	$ 295,000
Interest on debt conversion				1,022,502
Note Payable To Stockholder [Member]
Short-term Debt [Line Items]
Notes payable to stockholders		1,758,655	1,506,745	$ 1,758,655		$ 1,506,745	1,758,655
Debt instrument description				The notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 2016. All promissory notes are unsecured.		The notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 2016. All promissory notes are unsecured.
Promissory notes defaults values		1,340,156		$ 1,340,156			1,340,156
Convertible promissory notes yet to be converted		1,467,925	1,531,197	1,467,925		$ 1,531,197	1,467,925
Two-Year Convertible Promissory Note Dated August 10, 2016 [Member] \| Raymond Dabney - CEO [Member]
Short-term Debt [Line Items]
Notes payable to stockholders		670,407	670,407	670,407		$ 670,407	$ 670,407
Accrued management fees payable converted to convertible promissory notes	$ 975,407
Debt conversion price	$ 0.001
Debt conversion terms	The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and amortize it over the life of the Note.
Repayments of notes payable			$ 55,000
Interest on debt conversion				251,910
Two-Year Convertible Promissory Note Dated August 10, 2016 [Member] \| Raymond Dabney - CEO [Member] \| Rule 144 Restricted Stock [Member]
Short-term Debt [Line Items]
Shares issued for debt settlement agreement, shares							250,000,000
Shares issued for debt settlement agreement, value							$ 250,000
Shares issued, price per share			$ 0.001			$ 0.001
One-Year Convertible Promissory Note Dated October 01, 2016 [Member] \| Royalty Management Services Corp., - Company Owned By Family Member Of Mr. Raymond C. Dabney, CEO [Member]
Short-term Debt [Line Items]
Accrued management fees payable converted to convertible promissory notes									$ 710,790
Debt conversion price									$ 0.001
Repayments of notes payable		438,272
Convertible notes payable		272,518	$ 710,790	272,518		$ 710,790	272,518
Interest on debt conversion		533,092
One-Year Convertible Promissory Note Dated December 31, 2016 [Member] \| Royalty Management Services Corp., - Company Owned By Family Member Of Mr. Raymond C. Dabney, CEO [Member]
Short-term Debt [Line Items]
Accrued management fees payable converted to convertible promissory notes			$ 150,000			$ 150,000
Debt conversion price			$ 0.001			$ 0.001
Convertible notes payable		150,000	$ 150,000	150,000		$ 150,000	150,000
Interest on debt conversion				112,500
One-Year Convertible Promissory Note Dated May 31, 2017 [Member] \| Royalty Management Services Corp., - Company Owned By Family Member Of Mr. Raymond C. Dabney, CEO [Member]
Short-term Debt [Line Items]
Accrued management fees payable converted to convertible promissory notes								$ 375,000
Debt conversion price								$ 0.001
Convertible notes payable		$ 375,000	$ 0	375,000		$ 0	$ 375,000
Interest on debt conversion				$ 125,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

Equity Transactions (Narrative) (Details) - USD ($)										9 Months Ended
Equity Transactions (Narrative) (Details) - USD ($)	Sep. 30, 2017	Aug. 31, 2017	Aug. 10, 2017	May 17, 2017	May 05, 2017	Mar. 13, 2017	Mar. 07, 2017	Mar. 02, 2017	Feb. 16, 2017	Sep. 30, 2017
Common Class A [Member]
Common stock voting rights										These shares have 10 votes per share.
Series A Preferred Stock [Member]
Preferred stock voting rights										These shares have full voting rights of 67% on all shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State.
Common Shares [Member]
Common stock voting rights										These shares have full voting rights.
Shares issued for service during the period, shares										110,650,000
Common Shares [Member] \| Consulting Agreement [Member]
Total shares issued for service during the period, shares										121,500,000
Cancelled shares for non performance of services, shares	(7,350,000)									(10,850,000)
Cancelled shares for non performance of services, value	$ 371,695
Common Shares [Member] \| Consulting Agreement Dated January 13, 2017 [Member] \| Consultant [Member]
Shares issued for service during the period, shares									10,000,000
Shares issued for services during the period, value									$ 700,000
Common Shares [Member] \| Two Year Consulting Agreement [Member] \| 2016 Equity Award Plan B [Member]
Shares issued for service during the period, shares			25,000,000
Shares issued for services during the period, value			$ 1,062,500
Common Shares [Member] \| Consulting Agreement Dated March 7, 2017 [Member] \| 2016 Equity Award Plan B [Member]
Shares issued for service during the period, shares							15,000,000
Shares issued for services during the period, value							$ 1,270,500
Common Shares [Member] \| Consulting Agreement Dated July 06, 2016 [Member] \| 2016 Equity Award Plan B [Member]
Shares issued for service during the period, shares						10,000,000
Shares issued for services during the period, value						$ 883,000
Common Shares [Member] \| Consulting Agreement Dated April 29, 2015 [Member] \| 2016 Equity Award Plan B [Member]
Shares issued for service during the period, shares						15,000,000
Shares issued for services during the period, value						$ 1,324,500
Common Shares [Member] \| Two Year Consulting Agreement Dated August 10, 2017 [Member] \| 2016 Equity Award Plan B [Member]
Shares issued for service during the period, shares		30,000,000
Shares issued for services during the period, value		$ 1,392,000
Rule 144 Restricted Stock [Member] \| Consulting Agreement [Member] \| Two Consultants [Member]
Cancelled shares for non performance of services, shares	(3,500,000)
Cancelled shares for non performance of services, value	$ 107,750
Rule 144 Restricted Stock [Member] \| Consulting Agreement Dated January 13, 2017 [Member] \| Consultant [Member]
Shares issued for service during the period, shares									5,000,000
Shares issued for services during the period, value									$ 350,000
Rule 144 Restricted Stock [Member] \| Two Year Consulting Agreement [Member] \| Consultant [Member]
Shares issued for service during the period, shares								3,000,000
Shares issued for services during the period, value								$ 271,500
Rule 144 Restricted Stock [Member] \| One Year Consulting Agreement [Member] \| Consultant [Member]
Shares issued for service during the period, shares					7,000,000
Shares issued for services during the period, value					$ 469,000
Rule 144 Restricted Stock [Member] \| Three Month Marketing Agreement [Member] \| Consultant [Member]
Shares issued for service during the period, shares				15,000,000
Shares issued for services during the period, value				$ 93,600

XML 50 R39.htm IDEA: XBRL DOCUMENT

Equity Transactions (Narrative) (Details1) - USD ($)

9 Months Ended

Sep. 29, 2017

Aug. 10, 2017

Aug. 02, 2017

Apr. 18, 2017

Mar. 27, 2017

Jan. 24, 2017

Jan. 13, 2017

Sep. 16, 2011

Sep. 30, 2017

Common stock issued for stock option exercised, shares

75,000,000

Shares issued for stock option exercised, value

$ 3,038,226

Exercise price of stock options

$ 0.064

Common Shares [Member]

Common stock issued for stock option exercised, shares

60,000,000

Shares issued for stock option exercised, value

$ 60,000

Common Shares [Member] | Option Agreement [Member] | 2016 Equity Award Plan B [Member] | Consultant [Member]

Common stock issued for stock option exercised, shares

10,000,000

Shares issued for stock option exercised, value

$ 425,000

$ 465,000

$ 700,000

Exercise price of stock options

$ 0.02

$ 0.015

$ 0.05

Common Shares [Member] | Option Agreement [Member] | 2016 Equity Award Plan B [Member] | Consultant [Member]

Common stock issued for stock option exercised, shares

10,000,000

Shares issued for stock option exercised, value

$ 425,000

Exercise price of stock options

$ 0.03

Common Shares [Member] | Five Year Consulting Agreement [Member] | 2016 Equity Award Plan B [Member] | Consultant [Member]

Common stock issued for stock option exercised, shares

15,000,000

Shares issued for stock option exercised, value

$ 1,140,000

Exercise price of stock options

$ 0.075

No of shares agreed to be cancelled

(15,000,000)

Alfredo Dupetit-Bernardi - President/CEO of Cannabis Science Europe GmbH [Member] | Common Shares [Member] | Option Agreement [Member] | 2016 Equity Award Plan B [Member]

Common stock issued for stock option exercised, shares

10,000,000

Shares issued for stock option exercised, value

$ 815,000

Exercise price of stock options

$ 0.04

Dr. Allen Herman - Cheif Medical Officer [Member] | Common Shares [Member] | Option Agreement [Member] | 2016 Equity Award Plan B [Member]

Common stock issued for stock option exercised, shares

10,000,000

Shares issued for stock option exercised, value

$ 829,000

Exercise price of stock options

$ 0.02

Stock Option [Member]

Description of stock option expiration

Stock Option [Member] | V.P Of Investor Relations, CFO And Director For Services [Member]

Share based compensation option description

The following options were issued to the Company’s V.P of investor relations, CFO and Director for services under a September 16, 2011 agreement:

(i)

the option to purchase 100,000 common shares at ten cents ($0.10) per share;

(ii)

the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and

(iii)

the option to purchase 100,000 common shares at twenty cents ($0.20) per share;

(iv)

the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.

XML 51 R40.htm IDEA: XBRL DOCUMENT

Property Farming Rights (Narrative) (Details) - USD ($)							9 Months Ended
Property Farming Rights (Narrative) (Details) - USD ($)	May 18, 2017	Dec. 21, 2016	Dec. 18, 2016	Nov. 12, 2016	Oct. 24, 2016	Mar. 24, 2016	Sep. 30, 2017	Sep. 30, 2016	Oct. 09, 2017
Payment for property license for cultivation								$ 48,611
Computer [Member]
Useful life of related assets							2 years
Software [Member]
Useful life of related assets							2 years
Equipment And Laboratory Equipment [Member]
Useful life of related assets							5 years
Automobile [Member]
Useful life of related assets							3 years
Joint Venture License Agreement With Ft. McDermitt Allotment Land Allotees [Member]
Property farming license terms						On March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two initial payments of $50,000 for licensing and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.
Payment for property license for cultivation						$ 50,000
Master Facilitator Agreement With Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member]
Property farming license terms					On October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is 40% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp.
Renewal or extension terms					The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.
Exclusive Master Facilitator Agreement With Members of Washoe Tribal Allotments, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member]
Property farming license terms				On November 12, 2016, the Company entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp.
Renewal or extension terms				The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.
Six Exclusive Master Facilitator Agreement With Members of Washoe Tribal Allotments, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member]
Property farming license terms			On December 18, 2016, the Company enter six (9) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp.
Renewal or extension terms			The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.
Two Exclusive Master Facilitator Agreement With Members of Washoe Tribal Allotments, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University [Member]
Property farming license terms		On December 21, 2016, the Company enter two (2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp.
Renewal or extension terms		The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.
Exclusive Master Facilitator Agreement With Winnemucca Tribal MBS Of Neveda, Free Spirit Organics, LLC, American Education Consulting Group, Raymond C. Dabney University, American States University And Royalty Management Services Corp (RMS) [Member]
Property farming license terms	On May 18, 2017, the Company entered an Exclusive Master Facilitator Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit Organics, LLC (FSO), American Education Consulting Group, Raymond C. Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to lease and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and retain 5% of net profit as master facilitator.
Exclusive Master Facilitator Agreement With Winnemucca Tribal MBS Of Neveda, Free Spirit Organics, LLC, American Education Consulting Group, Raymond C. Dabney University, American States University And Royalty Management Services Corp (RMS) [Member] \| Subsequent Event [Member]
Wrote off of operating capital due to illegal seizure of cultivated industrial hemp									$ 212,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Equity Method Investee (Narrative) (Details) - OmniCanna Health Solutions, Inc. Related With Management - Director, CEO, CFO, COO [Member] - Equity Method Investment In OmniCanna Health Solutions, Inc. [Member] - USD ($)		9 Months Ended	12 Months Ended
	Nov. 05, 2014	Sep. 30, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Equity method investment description	This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.
Investment in marketable securities	$ 247,500	$ 85,277
Unrealized gain (loss) on marketable securities		$ (71,250)	$ 144,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

Goodwill And Intangible Assets (Narrative) (Details)	9 Months Ended
Goodwill And Intangible Assets (Narrative) (Details)	Sep. 30, 2017
Intellectual Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization computation method	Straight-line method
Intangible asset useful life	5 years
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization computation method	Straight-line method
Intangible asset useful life	5 years

XML 54 R43.htm IDEA: XBRL DOCUMENT

Subsequent Events (Narrative) (Details) - USD ($)						9 Months Ended
Subsequent Events (Narrative) (Details) - USD ($)	Oct. 27, 2017	Oct. 17, 2017	Aug. 10, 2017	Aug. 02, 2017	Jan. 13, 2017	Sep. 30, 2017
Subsequent Event [Line Items]
Common stock issued for stock option exercised, shares						75,000,000
Shares issued for stock option exercised, value						$ 3,038,226
Exercise price of stock options						$ 0.064
Common Shares [Member]
Subsequent Event [Line Items]
Common stock issued for stock option exercised, shares						60,000,000
Shares issued for stock option exercised, value						$ 60,000
Common Shares [Member] \| Option Agreement [Member] \| 2016 Equity Award Plan B [Member] \| Consultant [Member]
Subsequent Event [Line Items]
Common stock issued for stock option exercised, shares			10,000,000	10,000,000	10,000,000
Shares issued for stock option exercised, value			$ 425,000	$ 465,000	$ 700,000
Exercise price of stock options			$ 0.02	$ 0.015	$ 0.05
Subsequent Event [Member] \| Suit Against San Joaquin County and DEA For Illegal Seizure [Member]
Subsequent Event [Line Items]
Case suit filing date	October 27, 2017
Defendant name	The Company
Plaintiff name	San Joaquin County and DEA
Case allegations description	Iillegal seizure of cultivated industrial hemp crops from HRM Farm in Winnemucca Tribal Land for return of the seized properties.
Subsequent Event [Member] \| Common Shares [Member] \| Option Agreement [Member] \| 2016 Equity Award Plan B [Member] \| Consultant [Member]
Subsequent Event [Line Items]
Common stock issued for stock option exercised, shares		20,000,000
Shares issued for stock option exercised, value		$ 610,000
Exercise price of stock options		$ 0.025

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 194 214 1 false 88 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cannabisscience.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://cannabisscience.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://cannabisscience.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements Of Operations And Other Comprehensive Income (Loss) (Unaudited) Sheet http://cannabisscience.com/role/StatementsOfOperationsAndOtherComprehensiveIncomeLoss Consolidated Statements Of Operations And Other Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements Of Cash Flows (Unaudited) Sheet http://cannabisscience.com/role/StatementsOfCashFlows Consolidated Statements Of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements Of Stockholders' (Deficit) Sheet http://cannabisscience.com/role/StatementsOfStockholdersDeficit Consolidated Statements Of Stockholders' (Deficit) Statements 6 false false R7.htm 00000007 - Disclosure - Summary Of Significant Accounting Policies Sheet http://cannabisscience.com/role/SummaryOfSignificantAccountingPolicies Summary Of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://cannabisscience.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Fair Value Measurements And Disclosures Sheet http://cannabisscience.com/role/FairValueMeasurementsAndDisclosures Fair Value Measurements And Disclosures Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://cannabisscience.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://cannabisscience.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Equity Transactions Sheet http://cannabisscience.com/role/EquityTransactions Equity Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Equipment And Greenhouse Sheet http://cannabisscience.com/role/EquipmentAndGreenhouse Equipment And Greenhouse Notes 13 false false R14.htm 00000014 - Disclosure - Property Farming Rights Sheet http://cannabisscience.com/role/PropertyFarmingRights Property Farming Rights Notes 14 false false R15.htm 00000015 - Disclosure - Equity Method Investee Sheet http://cannabisscience.com/role/EquityMethodInvestee Equity Method Investee Notes 15 false false R16.htm 00000016 - Disclosure - Goodwill And Intangible Assets Sheet http://cannabisscience.com/role/GoodwillAndIntangibleAssets Goodwill And Intangible Assets Notes 16 false false R17.htm 00000017 - Disclosure - Prepaid Expenses And Deposits Held With RMS Sheet http://cannabisscience.com/role/PrepaidExpensesAndDepositsHeldWithRms Prepaid Expenses And Deposits Held With RMS Notes 17 false false R18.htm 00000018 - Disclosure - Commitments Sheet http://cannabisscience.com/role/Commitments Commitments Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Events Sheet http://cannabisscience.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Summary Of Significant Accounting Policies (Policies) Sheet http://cannabisscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary Of Significant Accounting Policies (Policies) Policies http://cannabisscience.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Related Party Transactions (Tables) Sheet http://cannabisscience.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://cannabisscience.com/role/RelatedPartyTransactions 21 false false R22.htm 00000022 - Disclosure - Equity Transactions (Tables) Sheet http://cannabisscience.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://cannabisscience.com/role/EquityTransactions 22 false false R23.htm 00000023 - Disclosure - Equipment (Tables) Sheet http://cannabisscience.com/role/EquipmentTables Equipment (Tables) Tables http://cannabisscience.com/role/EquipmentAndGreenhouse 23 false false R24.htm 00000024 - Disclosure - Property Farming Rights (Tables) Sheet http://cannabisscience.com/role/PropertyFarmingRightsTables Property Farming Rights (Tables) Tables http://cannabisscience.com/role/PropertyFarmingRights 24 false false R25.htm 00000025 - Disclosure - Goodwill And Intangible Assets (Tables) Sheet http://cannabisscience.com/role/GoodwillAndIntangibleAssetsTables Goodwill And Intangible Assets (Tables) Tables http://cannabisscience.com/role/GoodwillAndIntangibleAssets 25 false false R26.htm 00000026 - Disclosure - Prepaid Expenses And Deposits Held With RMS (Tables) Sheet http://cannabisscience.com/role/PrepaidExpensesAndDepositsHeldWithRmsTables Prepaid Expenses And Deposits Held With RMS (Tables) Tables http://cannabisscience.com/role/PrepaidExpensesAndDepositsHeldWithRms 26 false false R27.htm 00000027 - Disclosure - Related Party Transactions (Details) Sheet http://cannabisscience.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://cannabisscience.com/role/RelatedPartyTransactionsTables 27 false false R28.htm 00000028 - Disclosure - Equity Transactions (Schedule Of Stock Options Outstanding) (Details) Sheet http://cannabisscience.com/role/EquityTransactionsScheduleOfStockOptionsOutstandingDetails Equity Transactions (Schedule Of Stock Options Outstanding) (Details) Details http://cannabisscience.com/role/EquityTransactionsTables 28 false false R29.htm 00000029 - Disclosure - Equity Transactions (Schedule Of Weighted Average Fair Value Assumptions Of Stock Options) (Details) Sheet http://cannabisscience.com/role/EquityTransactionsScheduleOfWeightedAverageFairValueAssumptionsOfStockOptionsDetails Equity Transactions (Schedule Of Weighted Average Fair Value Assumptions Of Stock Options) (Details) Details http://cannabisscience.com/role/EquityTransactionsTables 29 false false R30.htm 00000030 - Disclosure - Equipment And Greenhouse (Details) Sheet http://cannabisscience.com/role/EquipmentAndGreenhouseDetails Equipment And Greenhouse (Details) Details http://cannabisscience.com/role/EquipmentAndGreenhouse 30 false false R31.htm 00000031 - Disclosure - Property Farming Rights (Details) Sheet http://cannabisscience.com/role/PropertyFarmingRightsDetails Property Farming Rights (Details) Details http://cannabisscience.com/role/PropertyFarmingRightsTables 31 false false R32.htm 00000032 - Disclosure - Goodwill And Intangible Assets (Details) Sheet http://cannabisscience.com/role/GoodwillAndIntangibleAssetsDetails Goodwill And Intangible Assets (Details) Details http://cannabisscience.com/role/GoodwillAndIntangibleAssetsTables 32 false false R33.htm 00000033 - Disclosure - Prepaid Expenses And Deposits Held With RMS (Details) Sheet http://cannabisscience.com/role/PrepaidExpensesAndDepositsHeldWithRmsDetails Prepaid Expenses And Deposits Held With RMS (Details) Details http://cannabisscience.com/role/PrepaidExpensesAndDepositsHeldWithRmsTables 33 false false R34.htm 00000034 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details) Sheet http://cannabisscience.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary Of Significant Accounting Policies (Narrative) (Details) Details http://cannabisscience.com/role/SummaryOfSignificantAccountingPoliciesPolicies 34 false false R35.htm 00000035 - Disclosure - Related Party Transactions (Narrative) (Details) Sheet http://cannabisscience.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions (Narrative) (Details) Details http://cannabisscience.com/role/RelatedPartyTransactionsTables 35 false false R36.htm 00000036 - Disclosure - Related Party Transactions (Narrative) (Details1) Sheet http://cannabisscience.com/role/RelatedPartyTransactionsNarrativeDetails1 Related Party Transactions (Narrative) (Details1) Details http://cannabisscience.com/role/RelatedPartyTransactionsTables 36 false false R37.htm 00000037 - Disclosure - Notes Payable (Narrative) (Details) Notes http://cannabisscience.com/role/NotesPayableNarrativeDetails Notes Payable (Narrative) (Details) Details http://cannabisscience.com/role/NotesPayable 37 false false R38.htm 00000038 - Disclosure - Equity Transactions (Narrative) (Details) Sheet http://cannabisscience.com/role/EquityTransactionsNarrativeDetails Equity Transactions (Narrative) (Details) Details http://cannabisscience.com/role/EquityTransactionsTables 38 false false R39.htm 00000039 - Disclosure - Equity Transactions (Narrative) (Details1) Sheet http://cannabisscience.com/role/EquityTransactionsNarrativeDetails1 Equity Transactions (Narrative) (Details1) Details http://cannabisscience.com/role/EquityTransactionsTables 39 false false R40.htm 00000040 - Disclosure - Property Farming Rights (Narrative) (Details) Sheet http://cannabisscience.com/role/PropertyFarmingRightsNarrativeDetails Property Farming Rights (Narrative) (Details) Details http://cannabisscience.com/role/PropertyFarmingRightsTables 40 false false R41.htm 00000041 - Disclosure - Equity Method Investee (Narrative) (Details) Sheet http://cannabisscience.com/role/EquityMethodInvesteeNarrativeDetails Equity Method Investee (Narrative) (Details) Details http://cannabisscience.com/role/EquityMethodInvestee 41 false false R42.htm 00000042 - Disclosure - Goodwill And Intangible Assets (Narrative) (Details) Sheet http://cannabisscience.com/role/GoodwillAndIntangibleAssetsNarrativeDetails Goodwill And Intangible Assets (Narrative) (Details) Details http://cannabisscience.com/role/GoodwillAndIntangibleAssetsTables 42 false false R43.htm 00000043 - Disclosure - Subsequent Events (Narrative) (Details) Sheet http://cannabisscience.com/role/SubsequentEventsNarrativeDetails Subsequent Events (Narrative) (Details) Details http://cannabisscience.com/role/SubsequentEvents 43 false false All Reports Book All Reports cbis-20170930.xml cbis-20170930.xsd cbis-20170930_cal.xml cbis-20170930_def.xml cbis-20170930_lab.xml cbis-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/currency/2017-01-31 true true ZIP 61 0001562884-17-000081-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001562884-17-000081-xbrl.zip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”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